



---

# RESEARCH OPPORTUNITIES ALERT!

---



**Issue 14: Volume 1a**  
**RESEARCH GRANTS FROM NIH**

**(QUARTER: JULY-SEPTEMBER, 2013)**

*A Compilation by the*

**Research Services Unit  
Office of Research, Innovation and Development (ORID)**

**June 2013**

JULY 2013

**V**ALIDATION OF NOVEL THERAPEUTIC TARGETS FOR HUNTINGTON'S DISEASE  
(R01)  
NIH: National Institute of Neurological Disorders and Stroke

**Description:**

The National Institute of Neurological Disorders and Stroke and the CHDI Foundation invite applications for their validation of novel therapeutic targets for Huntington's disease program. Applications are sought from researchers aiming to validate novel molecular targets for disease-modifying therapeutic intervention in Huntington's disease. Projects should advance the validation of molecular targets through genetic and pharmacological manipulation of the target in rodent or other in vivo mammalian models of Huntington's disease.

This funding opportunity announcement will utilize the R01 grant mechanism. Approximately \$4.5 million will be used to fund between three and four awards in 2011. The average direct costs per project will be \$250,000 per year over four years. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PAS-10-183

**Closing date: 01 Jul 13 (Forecast)**

**Deadline information: !! Call has not yet been announced by sponsor but this is the approximate deadline we expect. Deadline: June 30, 2010 and then every October 5, February 5 and June 5 annually thereafter.**

**Posted date: 04 May 10**

**Award type: Directed grants to institutions, research groups etc**

**Award budget total: \$4,500,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAS-10-183.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAS-10-183>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Huntington's Disease, Neurological Disorders, Intervention, Agents for (Health & Safety & Medical), Intervention, Types of (Health & Safety & Medical), Medical Genetics, Neurology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Clinical Laboratory Science, Neurodegenerative Disorders, Therapeutics

**Contact Details**

-----  
National Institute of Neurological Disorders and Stroke  
Neuroscience Center, Room 2222  
6001 Executive Blvd  
Bethesda, MD 20892-5745  
Tel+1 301 496 5680  
Email: [sutherlandm@ninds.nih.gov](mailto:sutherlandm@ninds.nih.gov)

## **P** ILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (R21)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

### **Description:**

The National Institute of Arthritis and Musculoskeletal and Skin Diseases invites applications for its pilot and feasibility clinical research grants in arthritis and musculoskeletal and skin diseases (R21) call. This call supports exploratory/developmental clinical research related to the prevention or treatment of arthritis and musculoskeletal and skin diseases, conditions, and/or injuries. The program is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to gather critical preliminary data in support of a future, planned clinical trial. They can include testing new or prevention strategies, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice.

This funding opportunity announcement will utilize the R21 grant mechanism. Direct costs are limited to \$275,000 over an R21 two-year period, with no more than \$200,000 in direct costs allowed in any single year. Applications will be accepted from domestic and foreign for-profit or nonprofit organizations and public or private institutions. PAR-10-282

**Closing date: 01 Jul 13**

**Deadline information: Deadlines on: 18 November 2010, 1 March 2011, 1 July 2011, 1 November 2011, 1 March 2012, 2 July 2012, 1 November 2012, 1 March 2013, 1 July 2013.**

**Posted date: 17 Sep 10**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-10-282.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-10-282>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Musculoskeletal System, Arthritis, Muscle Disorders, Rheumatic Diseases, Skeletal Diseases, Skin Diseases, Disease Prevention, Treatment, Medical, Dermatology, Rheumatology, Clinical Laboratory Sciences (RAE Unit 1), Clinical Laboratory Science

### **Contact Details**

-----  
Division of Skin and Rheumatic Diseases  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
One Democracy Plaza  
6701 Democracy Boulevard, Suite 800  
Bethesda, MD 20892-4872  
Tel: 1 301 594 1963  
Fax: 1 301 480 4543  
Email: [witterj@mail.nih.gov](mailto:witterj@mail.nih.gov)

# **T**UBERCULOSIS RESEARCH UNITS (U19) *NIH: National Institute of Allergy and Infectious Diseases*

## **Description:**

The National Institute of Allergy and Infectious Disease invites applications for its tuberculosis research units (U19). The purpose of this U19 funding opportunity announcement is to support the establishment of two to three multinational, multidisciplinary tuberculosis research units that will operate as a collaborative network to study tuberculosis latency and persistence and its relation to active TB disease, in humans and in animal models. This expansion aims to facilitate:

- pursuit of separate and distinct avenues of investigation;
- the ability to target different paucibacillary stages;
- conduct both hypothesis-generating and hypothesis-confirming studies;
- scientific depth and breadth to address paucibacillary stages of TB through integration of human studies and animal models.

Immunological studies and biomarker or bio-signature discovery projects that seek to improve strategies for therapeutic, vaccine and diagnostic development are of particular interest.

Each application must include a minimum of one clinical project and one animal research project. Research units must comprise administrative core, research projects, a clinical site and programmatic meetings. NIAID intends to commit US\$10 million in fiscal year 2014 to fund two to three units. Application budgets may request up to US\$3.25m in total direct costs in FY2014. The project award period is seven years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Only one

application per institution is allowed. RFA-AI-12-045.

**Closing date: 01 Jul 13**

**Deadline information:**

**Posted date: 07 Nov 12**

**Award type: Research centres,**

**Directed grants to institutions, research groups etc, Networking/collaboration**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-045.html>

**Application form:**

<http://grants.nih.gov/grants/funding/phs398/phs398.html>

## **Eligibility profile**

-----  
Nationality of applicant institution: Any

## **Disciplines**

-----  
Immunology, Immunopathology, Infectious Diseases & Agents, Pulmonary Diseases, Tuberculosis, Vaccine, Immunotherapy, Disease Model, Biochemical Markers, Biological Markers, Immunodiagnostics, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Medical and Biotechnology (Diagnostics), Community-based Clinical Subjects, Hospital-based Clinical Subject, Therapeutics, Animal Models

## **Contact Details**

-----  
Division of Microbiology and Infectious Diseases  
NIAID

6700 Rockledge Drive  
Bethesda, MD 20892

Tel: +1 301 435 2857  
Email: [csizemore@niaid.nih.gov](mailto:csizemore@niaid.nih.gov)

---

**N** **IDDK CENTRAL REPOSITORIES NON-RENEWABLE SAMPLE ACCESS (X01)**  
*NIH: National Institute of Diabetes and Digestive and Kidney Diseases*

**Description:**

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its central repositories non-renewable sample access (X01). The NIDDK central repositories house valuable samples and data taken from numerous major clinical studies. Researchers are invited to apply for access to these non-renewable samples. The collection of these samples from many different studies in the NIDDK central repositories has created a valuable resource with which researchers can rapidly validate clinical hypotheses and algorithms for clinical decision-making. The collection is also advancing the development of prognostic variables, biomarkers and therapeutics for diseases related to the NIDDK's mission.

This funding opportunity announcement will utilize the X01 grant mechanism. The total number of projects granted access to samples is dependent on NIH appropriations and the submission of a sufficient number of meritorious applications. Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. PAR 11-306 (replaces PAR-10-090)

**Closing date: 02 Jul 13**  
**Deadline information: Deadline time: 5pm.**  
**Deadlines on: 1 November 2011, 1 March 2012, 2 July 2012, 1 November 2012, 1 March**

**2013, 2 July 2013, 1 November 2013, 3 March 2014.**

**Posted date: 15 Aug 11**

**Award type: Equipment and materials, Access to laboratories, telescopes etc.**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-306.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-306>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Digestive System, Diabetes, Digestive Diseases & Disorders, Kidney Disease, Data Analysis, Clinical Laboratory Sciences (RAE Unit 1)

**Contact Details**

-----  
Division of Kidney, Urological and Hematological Diseases  
National Institute of Diabetes and Digestive and Kidney Diseases  
6707 Democracy Boulevard, Room 643  
Bethesda, MD 20892-5460  
Tel: +1 301 594 6007  
Email: [rr185i@nih.gov](mailto:rr185i@nih.gov)

## **P**ARTNERSHIPS FOR BIODEFENCE (R01)

NIH: National Institute of Allergy and Infectious Diseases

### **Description:**

The National Institute of Allergy and Infectious Diseases invites applications for its partnerships for biodefence (R01) grants. These support preclinical development of lead candidate therapeutics, vaccines and related technologies, or diagnostics against NIAID category A, B or C priority agents. Applications must include a product development strategy attachment and must demonstrate substantive investment by at least one industrial participant.

Total direct costs in any given year may not exceed US\$750,000. In addition, applicants may request up to a total of US\$300,000 for major equipment in the first year of the award to ensure that research aims can be met and biohazards can be contained. The total project period for an application cannot exceed five years.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. All applications must demonstrate substantive investment in the project by at least one industry participant. RFA-AI-13-013.

**Closing date: 02 Jul 13**

**Deadline information: Applications due by 5pm applicant's local time**

**Posted date: 27 Feb 13**

**Award type: Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration**

**Award budget total: \$20,000,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-013.html>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Terrorism, Domestic Terrorism, Immunogenetics, Immunology, Pharmacology, Infectious Diseases & Agents, Vaccine, Immunotherapy, Disease Model, Drug Design, Pathogenesis, Immunodiagnostics, Toxicology, Biological Warfare, Clinical Laboratory Sciences (RAE Unit 1), Pharmacology (RAE Unit 8), Biological Sciences (RAE Unit 14), Social Policy and Administration (RAE Unit 40), Clinical Laboratory Science

### **Contact Details**

-----  
Fax: +1 301 451 3758

Email: [mschaefer@niaid.gov](mailto:mschaefer@niaid.gov)

---

## **R**OLE OF THE MICROFLORA IN THE AETIOLOGY OF GASTROINTESTINAL CANCER (R01)

NIH: National Cancer Institute

### **Description:**

The National Cancer Institute and the National Institute on Alcohol Abuse and

Alcoholism invite applications for their role of the microflora in the aetiology of gastrointestinal cancer (R01) grants. This R01

funding opportunity announcement encourages innovative multidisciplinary research projects that will advance mechanistic understanding of microflora influences on gastrointestinal carcinogenesis. This FOA seeks applications that leverage and integrate information from large, meta-omic data sets to guide studies that identify critical microbial activities that can be mechanistically linked to GI carcinogenesis. Applicants may draw from existing large data sets, and may also propose to generate appropriate new data, including but not limited to data from both gene and protein analysis, such as DNA sequence and copy number, post-translational modifications, secreted signals, protein-protein interaction data between host factors and individual microbial species, or communities of microbes. The common goal of the projects should be to understand how the resident microbes interact with the host and the host environment to prevent or enhance carcinogenesis in the GI tract.

Domestic and foreign for-profit or non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. PAR-12-140.

**Closing date: 02 Jul 13**  
**Deadline information: Deadline: 2 July, 1 November 2012; 4 March, 2 July, 1 November 2013; 4 March 2014 by 5pm local time of applicant organisation.**  
**Posted date: 27 Mar 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-140.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-140>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Anatomical Systems & Sites, Cancer & Carcinogenesis, Aetiology, Physiological & Development Process, Gastroenterology, Biological Sciences, DNA Replication, DNA Sequencing, Genetics, Microbiology, Chemical Sciences, Biochemistry, Proteins, Clinical Laboratory Sciences (RAE Unit 1), Clinical Laboratory Science, Hospital-based Clinical Subject, Colorectal Cancer/Colon Cancer/Bowel Cancer

**Contact Details**

-----  
Division of Cancer Biology  
NCI  
6130 Executive Boulevard, EPN Suite 5014,  
MSC 7344  
Bethesda, MD 20892-7344  
Tel: +1 301 496 1951  
Email: [daschnep@mail.nih.gov](mailto:daschnep@mail.nih.gov)



## **C**ORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (UM1) *NIH: National Cancer Institute*

### **Description:**

The National Cancer Institute invites applications for its core infrastructure and methodological research for cancer epidemiology cohorts calls. This call supports UM1 grant applications to provide targeted infrastructure support for the core functions of cancer epidemiology cohorts (CECs) and methodological research. This infrastructure can support existing or new CECs. This funding opportunity announcement will support core functions for CECs currently funded through other grant mechanisms by the Epidemiology and Genetics Program and other components of the Division of Cancer Control and Population Sciences at the National Cancer Institute. Support is envisioned for two types of CECs through this FOA:

- CECs with at least 10,000 study participants that are capable of supporting studies to examine the effects of multiple exposures and study participants' characteristics on the risk of multiple types of incident cancers and cancer mortality;
- cohorts of cancer patients including at least 10,000 participants for research addressing determinants of cancer prognosis, progression, and cancer-related outcomes among cancer survivors such as cancer recurrence, development of new primaries, survival, and health conditions and chronic diseases related to the cancer, cancer-directed therapy, or its consequences.

This FOA will utilize the UM1 cooperative agreement award mechanism. Budget durations are not limited, but must reflect the actual needs of the project. A project duration of up to five years may be requested. Eligible organizations include domestic and foreign

public and private non-profit organizations and for-profit organizations. PAR-11-167 (replaces PAR-10-283)

**Closing date: 10 Jul 13**

**Deadline information: Deadlines on: 8 March 2011, 6 July 2011, 10 November 2011, 6 March 2012, 6 July 2012, 8 November 2012, 8 March 2013, 10 July 2013, 8 November 2013.**

**Posted date: 23 Mar 11**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration, Research centres**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-10-283.html>

**Application form:**

<http://grants.nih.gov/grants/funding/phs398/phs398.pdf>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Cancer Biology, Cancer & Carcinogenesis, Epidemiology, Clinical Laboratory Sciences (RAE Unit 1), Clinical Laboratory Science

### **Contact Details**

-----  
Division of Cancer Control and Population Sciences

National Cancer Institute, NIH

6130 Executive Boulevard, EPN Room 6142, MSC 7338

Bethesda, MD 20892-7338

Tel: +1 301 594 9499

Fax: +1 391 435 6609

Email: [winnde@mail.nih.gov](mailto:winnde@mail.nih.gov)



---

## **E**ARLY PHASE CLINICAL TRIALS IN IMAGING AND IMAGE-GUIDED INTERVENTIONS (R21) NIH: National Cancer Institute

---

### **Description:**

The National Cancer Institute invites applications for its early phase clinical trials in imaging and image-guided interventions (R21) grants. This R21 funding opportunity announcement is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3D reconstruction and other quantitative tools. This FOA will provide investigators with support for pilot cancer imaging clinical trials, including patient monitoring and laboratory studies. If proven successful, these investigations can be validated in larger studies through competitive R01 mechanisms or other clinical trials.

This FOA will use the NIH exploratory/developmental (R21) grant mechanism. Direct costs are limited to \$500,000 over a two-year period, with no more than \$250,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-216

**Closing date: 11 Jul 13**

**Deadline information: Deadlines: by 5 pm, July 27 and November 10, 2011; March 13, July 11 and November 13, 2012; March 13, July 11 and November 13, 2013; March 13, 2014.**

**Posted date: 26 May 11**

**Award type: Directed grants to institutions, research groups etc, Clinical trials**

**Award amount max: \$500,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-216.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-216>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Medical & Diagnostic Imaging, Cancer & Carcinogenesis, Disease Model, Mathematical Model (Medical), Imaging, Clinical Laboratory Sciences (RAE Unit 1), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Applied Mathematics (RAE Unit 23), Computer Science (RAE Unit 25), Electrical and Electronic Engineering (RAE Unit 29), Clinical Laboratory Science, Other Studies and Professions Allied to Medicine

### **Contact Details**

-----  
Cancer Imaging Program  
Division of Cancer Treatment and Diagnosis  
NCI  
6130 Executive Boulevard, EPN Room 6048,  
MSC 7412  
Bethesda, MD 20852-7412  
Tel: +1 301 496 9531  
Fax: +1 301 480 3507  
Email: [shankarl@mail.nih.gov](mailto:shankarl@mail.nih.gov)

## **DEVELOPMENT AND APPLICATION OF PET AND SPECT IMAGING LIGANDS AS BIOMARKERS FOR DRUG DISCOVERY AND FOR PATHOPHYSIOLOGICAL STUDIES OF CNS DISORDERS (R21)**

*NIH: National Institute of Mental Health*

### **Description:**

Participating institutes of the National Institutes of Health request R21 grant applications for the development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders phased innovation award.

R21 applications should propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in the human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

This FOA will utilise the exploratory or developmental (R21) award mechanism, and runs in parallel with FOA PA-13-158, which solicits applications using the NIH exploratory or developmental phased innovation R21/R33 award mechanism.

Direct costs are limited to US\$450,000 over a maximum of three years, with no more than US\$175,000 available in direct costs in any single year.

Eligible institutions include domestic or foreign for-profit and non-profit organisations and public or private institutions.

PA-13-157 (replaces PA-10-023).

**Closing date: 16 Jul 13**

**Deadline information: Applications due by 5pm proposer's local time, every 16 March, 16 July and 16 November annually until 8 May 2016.**

**Posted date: 26 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$475,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-157.html>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Clinical Psychology, Brain, Medical & Diagnostic Imaging, Pharmacology, Mental Disorders, Neurological Disorders, Pharmacokinetics, Molecular Probes, Molecular & Cellular Entities, Biochemical Markers, Receptors, Pathophysiology, Radiology, Neuroscience, Drug-Receptor Interaction, Radioisotopes, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Pre Clinical Studies (RAE Unit 5), Physiology (RAE Unit 7), Pharmacology (RAE Unit 8), Psychology (RAE Unit 13), Chemistry (RAE Unit 18), Neuroimaging, Clinical Laboratory Science, Pre-Clinical Studies, Neurodegenerative Disorders, Community-based Clinical Subjects, Physiology

### **Contact Details**

-----  
Fax: +1 301 443 3563

Email: [lbrady@mail.nih.gov](mailto:lbrady@mail.nih.gov)

## **DEVELOPMENT AND APPLICATION OF PET AND SPECT IMAGING LIGANDS AS BIOMARKERS FOR DRUG DISCOVERY AND FOR PATHOPHYSIOLOGICAL STUDIES OF CNS DISORDERS [PHASED INNOVATION (R21/R33)]**

*NIH: National Institute of Mental Health*

### **Description:**

Participating institutes of the National Institutes of Health request R21/R33 grant applications for the development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders phased innovation award.

Phased innovation R21/R33 applications should propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in the human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

This FOA will utilise the exploratory/developmental grant phased innovation grant (R21/R33) award mechanism, and runs in parallel with FOA PA-13-157, which solicits applications using the NIH exploratory/developmental R21 award mechanism.

Direct costs are limited to US\$175,000 per year for the R21 phase and US\$500,000 per year for the R33 phase, and neither phase can last longer than three years. The combined R21/R33 award is limited to five years in duration. Eligible institutions include domestic or foreign for-profit and non-profit organisations and public or private institutions. PAR-13-158 (replaces PA-10-024).

**Closing date: 16 Jul 13**

**Deadline information: Applications due by 5pm proposer's local time, every 16 March, 16 July and 16 November annually until 8 May 2016.**

**Posted date: 26 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-158.html>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Clinical Psychology, Brain, Medical & Diagnostic Imaging, Pharmacology, Mental Disorders, Neurological Disorders, Pharmacokinetics, Molecular Probes, Molecular & Cellular Entities, Biochemical Markers, Receptors, Pathophysiology, Radiology, Neuroscience, Drug-Receptor Interaction, Radioisotopes, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Pre Clinical Studies (RAE Unit 5), Physiology (RAE Unit 7), Pharmacology (RAE Unit 8), Psychology (RAE Unit 13), Chemistry (RAE Unit 18), Neuroimaging, Clinical Laboratory Science, Pre-Clinical Studies, Neurodegenerative Disorders, Community-based Clinical Subjects, Physiology

### **Contact Details**

-----  
Fax: +1 301 443 3563

Email: [lbrady@mail.nih.gov](mailto:lbrady@mail.nih.gov)

---

# **M** ECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21) NIH: National Institute of Nursing Research

---

## **Description:**

Participating institutes and centres of the National Institutes of Health invite applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R21 studies on pain as they relate to the missions of these ICs. Research may address: molecular and cellular mechanisms of pain; genetics of pain; biobehavioural pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This FOA will use the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-118 that utilises the R01 mechanism and PA-13-117, that utilises the R03 mechanism. Direct costs are limited to US\$275,000 over an R21 two-year period, with no more than US\$200,000 in direct costs allowed in any single year. Eligible organisations include for-profit and non-profit organisations, and public or private institutions. PA-13-119 (replaces PA-10-007).

**Closing date: 16 Jul 13**

**Deadline information: Applications due by 5pm applicant's local time, 16 March, 16 July and 16 November until 8 May 2016.**

**Posted date: 18 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-119.html>

## **Eligibility profile**

-----  
Nationality of applicant institution: Any

## **Disciplines**

-----  
Behavioural Medicine, Cardiovascular Diseases, Muscle Disorders, Neuromuscular Disorders, Osteoporosis, Pain, Skeletal Diseases, Skin Diseases, Behavioural Therapy, Chemotherapy, Diagnosis, Medical, Gene Therapy, Epidemiology, Neuropharmacology, Biology, Cellular, Biology, Molecular, Molecular Genetics, Biology, Behavioural, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Nursing (RAE Unit 10), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Cancer Care, Clinical Laboratory Science, Health Disparities, Oncology Nursing, Palliative Nursing, Geriatric Nursing, Community-based Clinical Subjects, Hospital-based Clinical Subject, Other Studies and Professions Allied to Medicine, Spinal Cord Injury

## **Contact Details**

-----  
National Institute of Nursing Research, NIH  
6701 Democracy Blvd., Suite 710  
One Democracy Plaza  
Bethesda, MD 20892-4870  
Tel:+1 301 496 9623  
Email: [mardens@mail.nih.gov](mailto:mardens@mail.nih.gov)

---

# **M** ECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R03) NIH: National Institute of Nursing Research

---

## **Description:**

Participating institutes and centres of the National Institutes of Health invite applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R03 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioural and social sciences. Research may address: molecular and cellular mechanisms of pain; genetics of pain; biobehavioural pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-119, that utilises the R01 mechanism and PA-13-118, that utilises the R21 mechanism. Budgets for direct costs of up to US\$50,000 per year and a project duration of up to two years may be requested for a maximum of US\$100,000 direct costs over a two-year project period. Eligible organisations include for-profit and non-profit organisations, and public or private institutions. PA-13-117 (replaces PA-10-008).

**Closing date: 16 Jul 13**

**Deadline information: Applications due by 5pm applicant's local time, every 16 March, 16 July and 16 November until 8 May 2016.**

**Posted date: 18 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-117.html>

## **Eligibility profile**

-----  
Nationality of applicant institution: Any

## **Disciplines**

-----  
Behavioural Medicine, Cardiovascular Diseases, Muscle Disorders, Neuromuscular Disorders, Osteoporosis, Pain, Skeletal Diseases, Skin Diseases, Behavioural Therapy, Chemotherapy, Diagnosis, Medical, Gene Therapy, Epidemiology, Neuropharmacology, Biology, Cellular, Biology, Molecular, Molecular Genetics, Biology, Behavioural, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Nursing (RAE Unit 10), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Cancer Care, Clinical Laboratory Science, Health Disparities, Oncology Nursing, Palliative Nursing, Geriatric Nursing, Community-based Clinical Subjects, Hospital-based Clinical Subject, Other Studies and Professions Allied to Medicine, Spinal Cord Injury

## **Contact Details**

-----  
National Institute of Nursing Research, NIH  
6701 Democracy Blvd., Suite 710  
One Democracy Plaza

Bethesda, MD 20892-4870  
Tel: +1 301 496 9623

Email: [mardens@mail.nih.gov](mailto:mardens@mail.nih.gov)

---

**D** **VELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS**  
**FOR RESEARCH (R21)**  
*NIH: Office of the Director*

**Description:**

The NIH Office of the Director invites applications for its development of animal models and related biological materials for research programme (R21).

This R21 announcement solicits proposals to develop, characterise or improve animal models for human disease, or to improve diagnosis and control diseases of laboratory animals that may interfere with research. Topics include: •disease models;

- genetically-modified animals and preservation of important disease models;
- fundamental biology of animal model systems;
- disease biomarkers;
- genetically encoded reporters;
- biological molecule interactive and functional networks;
- animal models for human rare disease conditions; •complementary approaches to use of animal models; animal diseases.

Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply.

Direct costs are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

PA-13-145 (replaces PA-10-138).

**Closing date: 16 Jul 13**

**Deadline information: Proposals due 5pm applicant's local time, every 16 March, 16 July and 16 November until 8 May 2016.**

**Posted date: 20 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-145.html>

**Application form:**

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Animal Behaviour & Ethology, Animal Diseases & Pathology, Animal Physiology & Morphology, Reproductive Biology, Animals, Vaccine, Gene Therapy, Disease Model, Biomedical Research Resources, Other, Transgenic Animals, Genetics, Regeneration, Computer Simulation & Modelling, Animal Research Policy, Ethics & Values in Science & Technology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Biological Sciences (RAE Unit 14), Veterinary Science (RAE Unit 17), Computer Science (RAE Unit 25), Philosophy (RAE Unit 62), Stem Cells, Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject

## Contact Details

---

DCM/ORIP/Division of Programme  
Coordination, Planning and Strategic  
Initiatives  
Office of the Director  
NIH

6701 Democracy Boulevard  
Bethesda MD 20892-4874  
Tel:+1 301 435 0744  
Fax:+1 301 480 3819  
Email: [oleg.mirchnitchenko@nih.gov](mailto:oleg.mirchnitchenko@nih.gov)

---

## **S** MALL GRANTS PROGRAM FOR CANCER EPIDEMIOLOGY (R03) NIH: *National Cancer Institute*

### Description:

The National Cancer Institute invites applications for its small grants program for cancer epidemiology. The goal of this R03 funding opportunity announcement is to provide support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology.

Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. This funding opportunity will utilize the NIH R03 small grant award mechanism. Budgets for direct costs of up to \$50,000 per year for a project duration of up to two years may be requested. PAR-12-039 (replaces PAR-08-237)

**Closing date: 23 Jul 13**

**Deadline information: Deadline: March 19, June 17, November 19, 2012; March 19, July 23, November 19, 2013; March 18, July 22, November 18, 2014.**

**Posted date: 29 Nov 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

### Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-039.html>

### Application form:

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-039>

### Eligibility profile

---

Nationality of applicant institution: Any

### Disciplines

---

Breast Cancer, Cancer & Carcinogenesis, Prostate Cancer, Aetiology, Biochemical Markers, Biological Markers, Epidemiology, Oncology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Blood Cancer, Community-based Clinical Subjects

### Contact Details

---

Division of Cancer Control and Population Sciences  
National Cancer Institute  
6130 Executive Boulevard, EPN Room 5104,  
MSC 7324  
Bethesda, MD 20892-7328  
Tel: +1 301 594 7344  
Fax: +1 301 402 4279  
Email: [vermam@mail.nih.gov](mailto:vermam@mail.nih.gov)

## **I**NNOVATION FOR HIV VACCINE DISCOVERY (R01)

NIH: National Institute of Allergy and Infectious Diseases

### **Description:**

The National Institute of Allergy and Infectious Disease invites applications for its innovation for HIV vaccine discovery (R01) grants. This R01 funding opportunity announcement encourage applications proposing innovative, high-risk, high-impact research to identify novel vaccine concepts and targets that will aid in the design and development of an effective immunogen that may provide long-term protection from acquisition of HIV. The emphasis is on early-discovery research that incorporates new ideas leading to the development of new conventional or outside-the-box approaches for vaccines that may have significant impact on the design of strategies for an effective vaccine.

NIAID intends to commit up to US\$3.05 million in fiscal year 2014 to fund five to 10 awards. Application budgets are limited to US\$350,000 per year in direct costs over a four-year period. Applicants may request an additional US\$150,000 in direct costs per year for any year when non-human primate research is proposed and justified.

The maximum project period is four years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The programme is open to established and new investigators and does not require research expertise in HIV prevention as a prerequisite for submitting an application. RFA-AI-13-007.

**Closing date: 24 Jul 13**

**Deadline information: Applications due by 5pm proposer's local time.**

**Posted date: 16 Jan 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$2,000,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-007.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-AI-13-007>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Immunity, Immunogenetics, Immunology, HIV Infection, Vaccine, Disease Prevention, Immunotherapy, Clinical Laboratory Sciences (RAE Unit 1), Social Policy and Administration (RAE Unit 40), Clinical Laboratory Science, Immunisation Programmes

### **Contact Details**

-----  
NIAID  
6700B Rockledge Drive, Room 5135  
Bethesda, MD 20817  
Tel: +1 301 496 0633  
Email: [jwarren@niaid.nih.gov](mailto:jwarren@niaid.nih.gov)



# **D**ELIVERING THERAPEUTICS TO RESIDUAL ACTIVE HIV RESERVOIRS (R01) *NIH: National Institute of Allergy and Infectious Diseases*

## **Description:**

The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their delivering therapeutics to residual active HIV reservoirs (R01) grants. This R01 funding opportunity announcement aims to solicit new ideas for eliminating cellular reservoirs of HIV that continue to actively produce virus in tissue compartments despite suppression of plasma viremia with antiretroviral therapy. New approaches to delivering antiretrovirals or other anti-HIV agents to these tissues or to specific cell types are needed to block virus production and infection, limit inflammation and facilitate clearance of these reservoir cells.

NIAID intends to commit up to US\$2.42 million and NIMN will commit up to US\$500,000 in fiscal year 2014 to fund awards. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. RFA-AI-12-042.

**Closing date: 24 Jul 13**

**Deadline information: Applications due by 5pm proposer's local time.**

**Posted date: 16 Jan 13**

**Award type: Directed grants to institutions, research groups etc, Innovation grants**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-042.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-AI-12-042>

## **Eligibility profile**

-----  
Nationality of applicant institution: Any

## **Disciplines**

-----  
AIDS, HIV Infection, Treatment, Medical, Retrovirus, Biology, Cellular, Viral Studies (Virology), Clinical Laboratory Sciences (RAE Unit 1),

Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Nursing (RAE Unit 10), Biological Sciences (RAE Unit 14), Clinical Laboratory Science, Cellular Pathology, Community-based Clinical Subjects, Hospital-based Clinical Subject, Therapeutics

## **Contact Details**

-----  
NIAID

6700B Rockledge Drive, Room 4149

Bethesda, MD 20817

Tel: +1 301 496 5332

Email: [salzwedelkd@mail.nih.gov](mailto:salzwedelkd@mail.nih.gov)

---

## **M** ECHANISMS OF CELLULAR IMMUNITY IN THE FEMALE REPRODUCTIVE TRACT (R01) NIH: National Institute of Allergy and Infectious Diseases

### **Description:**

The National Institute of Allergy and Infectious Diseases invites applications for its mechanisms of cellular immunity in the female reproductive tract (R01) grants.

This R01 call aims to develop the knowledge base needed to develop future vaccines that elicit effective and durable T-cell responses against infection by HIV and other viral pathogens in the female reproductive tract.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The overall budget for this call is US\$2 million. Funding is available for up to five years. Application budgets are not limited, but need to reflect the actual needs of the proposed project.  
RFA-AI-12-054.

**Closing date: 24 Jul 13**

**Deadline information: Applications due by 5pm proposer's local time.**

**Posted date: 08 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-054.html>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Transmission of HIV/AIDS, Human Reproduction & Fertility, Immune System, Immunology, Reproductive Physiology, HIV Infection, Reproductive Disorders, Health Care, Immune Enhancers, Vaccine, Lymphocytes, Pathogenesis, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Physiology (RAE Unit 7), Clinical Laboratory Science, Community-based Clinical Subjects, Physiology, Women's Health

### **Contact Details**

-----  
Fax: +1 301 435 3751

Email: [embrya@mail.nih.gov](mailto:embrya@mail.nih.gov)

---

## **M** UCOSAL ENVIRONMENT AND HIV PREVENTION (R01) NIH: National Institute of Allergy and Infectious Diseases

### **Description:**

The National Institute of Allergy and Infectious Diseases invites applications for its mucosal environment and HIV prevention (R01) grants.

These support innovative proof-of-concept and feasibility non-vaccine biomedical prevention research needed to support and advance the development of safer and more

effective microbicides, pre-exposure prophylaxis and multipurpose prevention technologies. This call address the following underserved areas:

- the role of the microbiome in transmission and acquisition of HIV and candidate safety and efficacy;
- tissue responses to prevention agents;
- the effect of genital secretions and hormones on susceptibility to HIV infection.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

The overall budget for this call is US\$5.9 million and application budgets are limited to US\$400,000 per year over a maximum of four years. Between eight and 14 awards will be funded.  
RFA-AI-13-012.

**Closing date: 25 Jul 13**

**Deadline information: Applications due 5pm local time of applicant organisation.**

**Posted date: 08 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$1,600,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-012.html>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Transmission of HIV/AIDS, Immunology, Reproductive Physiology, HIV Infection, Health Care, Disease Prevention, Biological Sciences, Clinical Laboratory Sciences (RAE Unit 1), Biological Sciences (RAE Unit 14), Clinical Laboratory Science

**Contact Details**

-----  
Fax: +1 301 451 2732

Email: [jturpin@niaid.nih.gov](mailto:jturpin@niaid.nih.gov)

---

## **R** ESearch in Latent Tuberculosis Infection in the Setting of HIV Co-Infection (R01)

*NIH: National Institute of Allergy and Infectious Diseases*

### **Description:**

The National Institute of Allergy and Infectious Diseases invites applications for its research in latent tuberculosis infection in the setting of HIV co-infection (R01) programme. This R01 funding opportunity announcement invites grant applications which propose research to increase the understanding of the microbiologic adaptive mechanisms, host immunologic factors, and their interactions involved in the development, maintenance, and activation of LTBI with a focus on HIV co-infection.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-061

**Closing date: 25 Jul 13**

**Deadline information: Deadlines on: 25 July 2013, 25 July 2014, 24 July 2015.**

**Posted date: 27 Dec 12**

**Award type: Directed grants to institutions, research groups etc**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-061.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-13-061>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Medical & Diagnostic Imaging, Immunology, HIV Infection, Tuberculosis, Immunotherapy, Bioassay, Biochemical Markers, Biological Markers, Drug Resistance, Microbial Processes, Microbiology, Clinical Laboratory Sciences (RAE Unit 1), Biological Sciences (RAE Unit 14), Clinical Laboratory Science

**Contact Details**

Division of Aids  
NIAID

6610 Rockledge Drive, MSC 6612  
Bethesda, MD 20892-6612

Tel: +1 301 402 5765

Email: [sudha.srinivasan@nih.gov](mailto:sudha.srinivasan@nih.gov)

---

**GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-RELATED DISORDERS (U01)**  
NIH: National Institute on Drug Abuse

**Description:**

The National Institute on Drug Abuse invites applications for its grand opportunity in medications development for substance-related disorders. This U01 funding opportunity announcement seeks to accelerate the development of medication for the treatment of substance-related disorders by supporting a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. Applications may focus on studying:

- new chemical entities;
- already-marketed pharmacotherapies;

- biologics (immunotherapies such as vaccines and antibodies, enzymes, gene therapies, etc);
- combinations of medications;
- new delivery devices/technologies.

This FOA will utilize the U01 grant mechanism. NIDA intends to commit up to \$15 million for a range of awards in fiscal year 2012. Awards will provide up to \$5 million in direct costs per year for up to three years.

Eligible applicants include foreign and domestic public or private institutions and non-profit or for-profit organizations. PAR-11-109

**Closing date: 26 Jul 13**

**Deadline information:** Deadline: letters of intent April 26 and July 26, 2011; February 27 and June 27, 2012; February 27 and June 27, 2013; full applications May 26 and August 26, 2011; March 27 and July 27, 2012; March 27 and July 26, 2013.

Posted date: 10 Feb 11

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: \$5,000,000

Award budget total: \$15,000,000

Website:

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-109.html>

Application form:

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-11-109>

#### Eligibility profile

Nationality of applicant institution: Any

#### Disciplines

Addictions, Drug & Substance Abuse, Nicotine Addiction & Withdrawal, Drug

Metabolism, Pharmacology, Pharmaceuticals, Opiates, Drug Resistance, Drug & Chemical Toxicology, Pharmaceutical Chemistry, Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Pharmacy (RAE Unit 9), Other Studies and Professions Allied to Medicine (RAE Unit 11), Psychology (RAE Unit 13), Chemistry (RAE Unit 18), Community-based Clinical Subjects, Hospital-based Clinical Subject, Other Studies and Professions Allied to Medicine, Translational Medicine, Prescription Medicine/Drugs

#### Contact Details

Division of Pharmacotherapies and Medical Consequences of Drug Abuse

NIDA

NIH

9000 Rockville Pike

Bethesda, MD 20892

Tel:+1 301 443 8639

Email: [imontoya@mail.nih.gov](mailto:imontoya@mail.nih.gov)

---

## **C**OOPERATIVE CENTERS FOR TRANSLATIONAL RESEARCH ON HUMAN IMMUNOLOGY AND BIODEFENSE (U19)

NIH: National Institute of Allergy and Infectious Diseases

#### Description:

The National Institute of Health's National Institute of Allergy and Infectious Diseases invites applications for its cooperative centers for translational research on human immunology and biodefense grants. These grants are designed to support hypothesis-testing, mechanistic studies on the activation and regulation of human immune responses in the context of infectious disease. The immediate objectives are to support research on human immunological responses to infection, vaccination against infectious disease, or administration of vaccine

adjuvants that target innate immune receptors and to support the stable, flexible, centralised infrastructure needed to promote and coordinate multidisciplinary research in human immunology as it relates to defence against infectious disease.

This funding opportunity will utilise the U19 award mechanism. It is anticipated that approximately US\$20 million in total costs will be available in financial year 2014 to fund six to seven awards. Applicants may request no more than US\$1.75m direct costs per year for up to five years.

Eligible applicants include domestic or foreign public and private institutions and non-profit or for-profit organisations. RFA-AI-13-016 (replaces RFA-AI-08-014).

**Closing date: 29 Jul 13**

**Deadline information: Letters of intent due June 28; full applications due July 29, 2013.**

**Posted date: 22 Mar 13**

**Award type: Research centres, Directed grants to institutions, research groups etc**

**Award amount max: \$8,750,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-016.html>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

Immune System, Immunology, Infectious Diseases & Agents, Vaccine, Immunotherapy, Allergy, Bacteriology, Viral Studies (Virology), Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Translational Medicine, Anti-Microbial Agents

**Contact Details**

-----  
Division of Allergy, Immunology and Transplantation

National Institute of Allergy and Infectious Diseases

BG 6610 Room 6308

6610 ROCKLEDGE DR

BETHESDA MD 20817

Tel: +1 301 435 4416

Email: [hquill@niaid.nih.gov](mailto:hquill@niaid.nih.gov)



**AUGUST 2013**

**A** **DVANCING EXCEPTIONAL RESEARCH ON HIV/AIDS (R01)**  
*NIH: National Institute on Drug Abuse*

**Description:**

The National Institute on Drug Abuse invites applications for its advancing exceptional research on HIV/Aids (R01)programme. This R01 funding opportunity announcement will support highly innovative applications on HIV/Aids and drug abuse. The focus is on innovative research projects that have the potential to open new areas of HIV/Aids research or lead to new avenues for prevention and treatment of HIV/Aids among substance abusers. Applications are required to have a detailed research plan and preliminary data. This call is not limited to any one area of research. This FOA will complement the NIH avant-garde programme.

This FOA is open to both individual researchers and research teams. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

NIDA intends to commit US\$2 million in fiscal year 2014 to fund two to three awards. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. RFA-DA-14-003 (replaces RFA-DA-13-008).

**Closing date: 01 Aug 13**

**Deadline information: Letters of intent due by 1 July; full applications by 5pm local time, 1 August 2013.**

**Posted date: 21 Mar 13**

**Award type: Directed grants for individual investigators, Directed grants to**

**institutions, research groups etc, Innovation grants**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-14-003.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-DA-14-003>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Drug & Substance Abuse, Transmission of HIV/AIDS, AIDS Counselling, AIDS, HIV Infection, Intervention, Agents for (Health & Safety & Medical), Intervention, Types of (Health & Safety & Medical), Disease Prevention, Preventive Medicine, Treatment, Medical, Pathogenesis, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, HIV Tests

**Contact Details**

-----  
NIDA  
NIH  
6001 Executive Boulevard  
Bethesda, MD 20892  
Tel: +1 301 402 1919  
Email: [jnormand@mail.nih.gov](mailto:jnormand@mail.nih.gov)

## **P**RECLINICAL INNOVATION PROGRAMME (R01) *NIH: National Institute of Allergy and Infectious Diseases*

### **Description:**

The National Institute of Allergy and Infectious Diseases invites applications for its preclinical innovation programme (R01).

This R01 call supports high risk and innovative research and development efforts designed to establish and maintain a sustainable pipeline of non-vaccine biomedical prevention candidates, drug delivery systems and supporting technologies for the prevention of HIV acquisition and transmission.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The overall budget for this call is US\$3.5 million, to fund between four and eight awards. Applicants may request up to US\$400,000 in direct costs per year, over a maximum of four years.

RFA-AI-13-008.

**Closing date: 01 Aug 13**

**Award amount max: \$1,600,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-008.html>

**Deadline information: Applications due by 5pm proposer's local time.**

**Posted date: 08 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Transmission of HIV/AIDS, Pharmacy, HIV Infection, Drug Delivery Systems, Disease Prevention, Screening of Drugs & Agents, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Pharmacy (RAE Unit 9), Clinical Laboratory Science, Community-based Clinical Subjects

### **Contact Details**

-----  
Fax: +1 301 451 2732

Email: [jturpin@niaid.nih.gov](mailto:jturpin@niaid.nih.gov)

---

## **N**EURONEXT CLINICAL TRIALS (U01) *NIH: National Institute of Neurological Disorders and Stroke*

### **Description:**

The National Institute of Neurological Disorders and Stroke invites applications for its NeuroNEXT clinical trials U01 grants. This encourages applications for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or

devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy in the treatment of neurologic disease. Applications for drugs or biologics should provide compelling scientific evidence that the investigational agent



proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests. Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.

This FOA uses the research project - cooperative agreements U01 funding mechanism and runs parallel to FOAs of similar scientific scope PAR-11-344 that uses the resource access award X01 funding mechanism and PAR-11-345 that uses the small business innovation research (SBIR) cooperative agreement - phase II and fast-track U44 funding mechanism, however this is available for US based candidates only. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum request cannot exceed five years but the actual funded project period is dependent on reaching specific milestones as described in this FOA. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Applications are accepted from non-US entities, foreign components of US based organisations and

components of US organizations, but they will have to work with the US-based NeuroNEXT infrastructure.

PAR-11-343

**Closing date: 02 Aug 13**

**Deadline information: Deadline time: 5pm local time of applicant organisation**

**Posted date: 22 Sep 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-343.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-343>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Disease Prevention, Clinical Trial, Biochemical Markers, Biological Markers, Research Resources (Health & Safety & Medical), Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Hospital-based Clinical Subject

**Contact Details**

-----  
Fax: +1 301 496 9135

Email: [mcneilde@ninds.nih.gov](mailto:mcneilde@ninds.nih.gov)



## **LIMITED COMPETITION - REVISION APPLICATIONS FOR BASIC SOCIAL AND BEHAVIOURAL RESEARCH ON THE SOCIAL, CULTURAL, BIOLOGICAL AND PSYCHOLOGICAL MECHANISMS OF STIGMA (R01)**

NIH: National Cancer Institute

### **Description:**

The National Cancer Institute, as well as 27 other departments of the National Institutes for Health, invites proposals for its limited competition for revision applications for basic social and behavioural research on the social, cultural, biological and psychological mechanisms of stigma (R01) grants.

This R01 OppNet call encourages revision applications to incorporate basic research on behavioural and social mechanisms underlying stigma into active R01 research projects. Projects may focus on stigma processes and mechanisms from the perspective of stigmatised individuals or groups, or of individuals or groups holding stigmatising beliefs.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The budget for this call is approximately US\$1 million and direct costs may not exceed US\$100,000 over a one-year period. An estimated six to seven awards are available. RFA-MD-13-005.

**Closing date: 02 Aug 13**

**Deadline information: Proposals due 5pm applicant's local time.**

**Posted date: 27 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

**Award budget total: \$1,000,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-13-005.html>

**Application form:**

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Prejudice, Ethnicity & Alcohol Studies, Community & Outreach Programmes, Addictions, Alcohol & Alcoholism, Drug & Substance Abuse, Transmission of HIV/AIDS, AIDS Counselling, Mental Health, Race & Community Relations, Discrimination, Alienation, Social & Personal Relationships, Social Attitudes, Social Behaviour, Alcohol Education, AIDS, Cancer & Carcinogenesis, Emotional & Mental Health, HIV Infection, Infectious Diseases & Agents, Mental Health Services, AIDS & Employment Studies, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Nursing (RAE Unit 10), Psychology (RAE Unit 13), Social Policy and Administration (RAE Unit 40), Social Work (RAE Unit 41), Sociology (RAE Unit 42), Business and Management Studies (RAE Unit 43), Philosophy (RAE Unit 62), Education (RAE Unit 68), Health Education, Cancer Care, Clinical Laboratory Science, Health Disparities, Community-based Clinical Subjects, Hospital-based Clinical Subject, HIV/AIDS, Social Aspects, Mental Health, Social Aspects, HIV Tests, Social Inequality

### **Contact Details**

-----  
NIMHD  
Building 2DEM, Room 800  
6707 Democracy Blvd  
Bethesda MD 20817  
Tel: +1 301 594 9567  
Email: [alvidrezj@mail.nih.gov](mailto:alvidrezj@mail.nih.gov)

# **H**IGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R03) NIH: National Institute of Mental Health

## **Description:**

Five institutes and centres of the National Institutes of Health invite applications for their high throughput screening to discover chemical probes (R03) grants. This R03 funding opportunity announcement aims to promote and support discovery and development of new chemical probes as research tools for use to advance understanding of biological functions and disease mechanisms. The FOA encourages partnerships between assay submitters and a discovery facility to conduct joint research. Funding will stimulate research in:

- the discovery and development of novel, small molecules for their potential use in studying disease treatment;
- the discovery or validation of novel, biological targets that will inform studies of disease mechanisms.

Direct costs are limited to US\$100,000 over a two-year period, with no more than US\$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-135.

**Closing date: 06 Aug 13**

**Deadline information: Applications due by 5pm local time of applicant organisation. Deadlines on: 6 August 2013, 4 December 2013, 4 April 2014, 6 August 2014, 4 December 2014, 3 April 2015, 6 August 2015, 4 December 2015.**

**Posted date: 07 Mar 13**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration, Innovation grants**  
**Award amount max: \$100,000**

## **Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-135.html>

## **Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-135>

## **Eligibility profile**

-----  
Nationality of applicant institution: Any

## **Disciplines**

-----  
Biomedical, Medical Sciences, Health, Medicinal Chemistry, Disease Entities & Medical Problems & Behaviour, Bioassay, Disease Model, Molecular Probes, Clinical Laboratory Sciences (RAE Unit 1), Chemistry (RAE Unit 18), Clinical Laboratory Science

## **Contact Details**

-----  
Division of Neuroscience and Basic Behavioral Science  
NIMH  
6001 Executive Boulevard, Room 7182B, MSC 9641  
Bethesda, MD 20892-9641  
Tel: +1 301 443 6102  
Email: [yyao@mail.nih.gov](mailto:yyao@mail.nih.gov)



## **G** RAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-RELATED DISORDERS (R01): AIDS RELATED NIH: National Institute on Drug Abuse

### **Description:**

The National Institute on Drug Abuse invites applications for its grand opportunity in medications development for substance-related disorders. This U01 Aids-related funding opportunity announcement seeks to accelerate the development of medication for the treatment of substance-related disorders by supporting a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. Applications may focus on studying:

- new chemical entities;
- already-marketed pharmacotherapies;
- biologics (immunotherapies such as vaccines and antibodies, enzymes, gene therapies, etc);
- combinations of medications;
- new delivery devices/technologies.

This FOA will utilize the U01 grant mechanism. NIDA intends to commit up to \$15 million for a range of awards in fiscal year 2012. Awards will provide up to \$5 million in direct costs per year for up to three years.

Eligible applicants include foreign and domestic public or private institutions and non-profit or for-profit organizations. PAR-11-109

**Closing date: 14 Aug 13**

**Deadline information: Deadline: letters of intent April 26 and July 26, 2011; February 27 and June 27, 2012; February 27 and June 27, 2013; full applications August 14 and November 8, 2011; March 27 and August 14, 2012; March 27 and August 14, 2013.**

**Posted date: 10 Feb 11**

**Award type: Directed grants to institutions, research groups etc,**

**Networking/collaboration**

**Award amount max: \$5,000,000**

**Award budget total: \$15,000,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-109.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-109>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Addictions, Drug & Substance Abuse, Nicotine Addiction & Withdrawal, Transmission of HIV/AIDS, Drug Metabolism, Pharmacology, AIDS, HIV Infection, Pharmaceuticals, Opiates, Drug Resistance, Drug & Chemical Toxicology, Pharmaceutical Chemistry, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Pharmacy (RAE Unit 9), Other Studies and Professions Allied to Medicine (RAE Unit 11), Psychology (RAE Unit 13), Chemistry (RAE Unit 18), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Other Studies and Professions Allied to Medicine, Translational Medicine, Prescription Medicine/Drugs

### **Contact Details**

-----  
Division of Pharmacotherapies and Medical Consequences of Drug Abuse  
NIDA  
NIH

9000 Rockville Pike  
Bethesda, MD 20892

Tel: +1 301 443 8639  
Email: [imontoya@mail.nih.gov](mailto:imontoya@mail.nih.gov)

---

**F**UNCTIONAL CHARACTERISATION OF ORAL CANCER INITIATING CELLS  
*NIH: National Institute of Dental and  
Craniofacial Research*

**Description:**

The National Institutes of Health's National Institute of Dental and Craniofacial Research invites applications for its functional characterisation of oral cancer initiating cells grant. This R21 opportunity solicits applications to facilitate translational research in oral cancers by supporting studies aimed at understanding the cellular, molecular and functional properties of oral cancer initiating cells and their niches. The primary objective of this call is to elucidate the cellular origins, molecular properties and functional roles of these cells and their microenvironment to create knowledge that can be used to facilitate the development of new targeted and effective therapies for oral squamous cell carcinomas.

This FOA will use the R21 exploratory/developmental award mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-13-002, which encourages applications under the R01 research project grant mechanism. In fiscal year 2014, the NIDCR will commit approximately US\$1.5 million, to fund four to six grants across both mechanisms, with two to three awards in each mechanism. Application budgets are limited to US\$275,000 over a two-year period, with no more than US\$200,000 in any year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. RFA-DE-14-002.

**Closing date: 15 Aug 13**

**Deadline information: Proposals due 5pm applicant's local time.**

**Posted date: 28 Mar 13**

**Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc.**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-14-002.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-DE-14-002>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Cancer Biology, Cancer & Carcinogenesis, Oral Diseases, Tumour Immunology, Dentistry, Oncology, Clinical Laboratory Sciences (RAE Unit 1), Clinical Dentistry (RAE Unit 4), Clinical Laboratory Science, Oral and Maxillofacial Surgery, Oral Medicine, Oral Pathology

**Contact Details**

-----  
NIDCR  
Epithelial Cell Regulation and Transformation Programme  
45 Center Drive, MSC 6400  
Bethesda, MD 20892-6400  
Tel: +1 301 594 4812  
Email: [sundarv@nih.gov](mailto:sundarv@nih.gov)

## **F**UNCTIONAL CHARACTERISATION OF ORAL CANCER INITIATING CELLS *NIH: National Institute of Dental and Craniofacial Research*

### **Description:**

The National Institutes of Health's National Institute of Dental and Craniofacial Research invites applications for its functional characterisation of oral cancer initiating cells grant. This R01 opportunity solicits applications to facilitate translational research in oral cancers by supporting studies aimed at understanding the cellular, molecular and functional properties of oral cancer initiating cells and their niches. The primary objective of this call is to elucidate the cellular origins, molecular properties and functional roles of these cells and their microenvironment to create knowledge that can be used to facilitate the development of new targeted and effective therapies for oral squamous cell carcinomas.

This FOA will use the R01 research project grant mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-13-002, which encourages applications under the R21 exploratory/developmental award mechanism. In fiscal year 2014, the NIDCR will commit approximately US\$1.5 million, to fund four to six grants across both mechanisms, with two to three awards in each mechanism. Application budgets are expected to vary, but the maximum project period will be four years. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. RFA-DE-14-001.

**Closing date: 15 Aug 13**

**Deadline information: Proposals due 5pm applicant's local time.**

**Posted date: 28 Mar 13**

**Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-14-001.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-DE-14-001>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Cancer Biology, Cancer & Carcinogenesis, Oral Diseases, Tumour Immunology, Dentistry, Oncology, Clinical Laboratory Sciences (RAE Unit 1), Clinical Dentistry (RAE Unit 4), Clinical Laboratory Science, Oral and Maxillofacial Surgery, Oral Medicine, Oral Pathology

### **Contact Details**

-----  
NIDCR  
Epithelial Cell Regulation and Transformation Programme  
45 Center Drive, MSC 6400  
Bethesda, MD 20892-6400  
Tel: +1 301 594 4812  
Email: [sundarv@nih.gov](mailto:sundarv@nih.gov)

## **N**INDS COOPERATIVE PROGRAMME IN TRANSLATIONAL RESEARCH (U01) *NIH: National Institute of Neurological Disorders and Stroke*

### **Description:**

The National Institute of Neurological Disorders and Stroke invites applications for its cooperative programme in translational research (U01). This U01 funding opportunity will support preclinical development and testing of new therapies for neurological disorders. It will facilitate encouragement, development and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. Projects must include therapeutic leads and in vivo proof of concept on efficacy. The programme supports preclinical optimisation and testing of the leads, and projects must be sufficiently advanced that an application may be submitted to the Food and Drug Administration during the project period. The programme can also support phase 0 clinical trials for small molecule drugs, proof-of-concept for biologics or proof-of-concept or pilot clinical trials for therapeutic devices.

This FOA will use the U01 cooperative agreement award mechanism and runs in parallel an FOA of identical scientific scope, PAR-13-023, which solicits applications under the research project grant (R21) award mechanism. Award budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-022 (replaces PAR-11-294).

**Closing date: 20 Aug 13**

**Deadline information: Proposals due by 5pm, local time of applicant organisation.**

**Deadlines on: 7 February 2013, 20 August 2013, 7 February 2014, 20 August 2014.**

**Posted date: 20 Nov 12**

**Award type: Networking/collaboration, Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-022.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-022>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Pharmacology, Neurological Disorders, Disease Model, Neurology, Neuropharmacology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Nursing (RAE Unit 10), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Translational Medicine, Therapeutics

### **Contact Details**

-----  
Neuroscience Center, Rm 2227

NINDS

6001 Executive Blvd

Bethesda, MD 20892

Tel: +1 301 496 1779

Email: [mcgavernlm@ninds.nih.gov](mailto:mcgavernlm@ninds.nih.gov)

**NINDS COOPERATIVE PROGRAMME IN TRANSLATIONAL RESEARCH (U01):  
AIDS-RELATED**  
NIH: National Institute of Neurological  
Disorders and Stroke

**Description:**

The National Institute of Neurological Disorders and Stroke invites applications for its Aids-related cooperative programme in translational research (U01). This Aids-related U01 funding opportunity will support preclinical development and testing of new therapies for neurological disorders. It will facilitate encouragement, development and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. Projects must include therapeutic leads and in vivo proof of concept on efficacy. The programme supports preclinical optimisation and testing of the leads, and projects must be sufficiently advanced that an application may be submitted to the Food and Drug Administration during the project period. The programme can also support phase 0 clinical trials for small molecule drugs, proof-of-concept for biologics or proof-of-concept or pilot clinical trials for therapeutic devices.

This FOA will use the U01 cooperative agreement award mechanism and runs in parallel an FOA of identical scientific scope, PAR-13-023, which solicits applications under the research project grant (R21) award mechanism. Award budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-022 (replaces PAR-11-294).

**Closing date: 20 Aug 13**

**Deadline information: Proposals due by 5pm, local time of applicant organisation.**

**Deadlines on: 4 April 2013, 20 August 2013, 4 April 2014, 20 August 2014.**

**Posted date: 20 Nov 12**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-022.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-022>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Pharmacology, AIDS, HIV Infection, Neurological Disorders, Neurology, Neuropharmacology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Nursing (RAE Unit 10), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Translational Medicine, Therapeutics

**Contact Details**

-----  
Neuroscience Center, Rm 2227  
NINDS

6001 Executive Blvd

Bethesda, MD 20892

Tel: +1 301 496 1779

Email: [mcgavernlm@ninds.nih.gov](mailto:mcgavernlm@ninds.nih.gov)



## **I** INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01): AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

### **Description:**

The National Institute of Allergy and Infectious Diseases invites applications for its international research in infectious diseases program. This R01 funding opportunity announcement solicits applications from organizations/institutions in eligible foreign countries that propose research related to infectious diseases that are of interest to that country. The intent of these activities is to advance the development of local scientific expertise, build local research infrastructure and to increase collaborative research partnerships at NIAID international sites. Collaborative projects involving investigators and institutions from international sites and the US are particularly encouraged; a US partner is not required.

This announcement will use the NIH research project grant (R01) award mechanism. Budgets for direct costs of up to \$125,000 per year and a project duration of up to five years may be requested for a maximum of \$625,000 direct costs over a five-year project period. Eligible organizations include for-profit or non-profit organizations and public or private institutions in developing countries. Principal investigators may not currently hold a NIH funded grant. PAR-11-145 (replaces PAR-08-130)

**Closing date: 23 Aug 13**

**Deadline information: Deadline: letters of intent 30 days prior to application due date. Deadlines on: 23 August 2011, 23 August 2012, 23 August 2013.**

**Posted date: 28 Mar 11**

**Award type: Directed grants to institutions, research groups etc, Networking/collaboration**

**Award amount max: \$625,000**

### **Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-145.html>

### **Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-145>

### **Eligibility profile**

-----  
Nationality of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries

### **Disciplines**

-----  
Transmission of HIV/AIDS, Immunology, Immunopathology, AIDS, HIV Infection, Infectious Diseases & Agents, Parasitic Diseases, Sexually Transmitted Diseases, Tuberculosis, International Health, Pathogenesis, Epidemiology, Microbiology, Viral Studies (Virology), Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Other Studies and Professions Allied to Medicine (RAE Unit 11), Biological Sciences (RAE Unit 14), Malaria, Biostatistics, Clinical Laboratory Science, Other Studies and Professions Allied to Medicine

### **Contact Details**

-----  
Division of Microbiology and Infectious Diseases  
NIAID  
Room 3807, MSC-6603  
6610 Rockledge Drive  
Bethesda, MD 20892-6603  
Tel: +1 301 496 1884  
Email: [ps31g@nih.gov](mailto:ps31g@nih.gov)

## **E**VALUATION OF THE LATENT RESERVOIR IN HIV-INFECTED INFANTS AND CHILDREN WITH EARLY ANTIRETROVIRAL TREATMENT AND VIROLOGIC CONTROL (R01)

—NIH: National Institute of Child Health and Human Development

### **Description:**

The National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Disease invite applications for their evaluation of the latent reservoir in HIV-infected infants and children with early antiretroviral treatment and virologic control (R01) grants. This R01 funding opportunity announcement supports studies of the latent reservoir in HIV-infected children who may have had early treatment and have had continuous viral suppression. Studies to create new or adapt existing animal models of perinatal HIV infection and early treatment can also be proposed.

The studies can be in developing or developed countries. systems or diseases of interest to the participating institutes.

NICHD intends to commit US\$1.5 million and NIAID intends to commit US\$1.4m to fund between three and six awards each. Application budgets are limited to less than US\$750,000 in direct costs per year over five years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. RFA-HD-14-026.

**Closing date: 30 Aug 13**

**Deadline information: Applications due by 5pm proposer's local time.**

**Posted date: 07 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$3,750,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-14-026.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-HD-14-026>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Transmission of HIV/AIDS, AIDS, HIV Infection, Treatment, Medical, Retrovirus, Paediatrics, Viral Studies (Virology), Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Nursing (RAE Unit 10), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject, Therapeutics

### **Contact Details**

-----  
Maternal and Pediatric Infectious Disease Branch

NICHD

NIH

6100 Executive Boulevard, Room 4B11

Bethesda, MD 20892

Tel: +1 301 435 6868

Email: [hazrar@mail.nih.gov](mailto:hazrar@mail.nih.gov)

**S** AFETY AND EFFECTIVENESS OF TRIPLE ANTIRETROVIRAL DRUG STRATEGIES FOR PREVENTION OF MOTHER-TO-CHILD HIV TRANSMISSION (R01)  
NIH: National Institute of Child Health and Human Development

**Description:**

The National Institute of Child Health and Human Development invites applications for its safety and effectiveness of triple antiretroviral drug strategies for prevention of mother-to-child HIV transmission (R01) grants. This R01 funding opportunity announcement aims to evaluate the safety and effectiveness of implementation of triple antiretroviral drug strategies for prevention of mother-to-child HIV transmission in resource-constrained settings. Approaches may include either stopping antiretroviral drugs after breastfeeding cessation in women who don't require therapy for their own health or a strategy in which life-long antiretroviral therapy is started in all pregnant women regardless of immune or clinical status.

NICHD intends to commit US\$5 million to fund five to 10 awards in fiscal year 2014. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. RFA-HD-14-027.

**Closing date: 30 Aug 13**

**Deadline information: Applications due by 5pm, proposer's local time.**

**Posted date: 12 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: \$5,000,000**

**Website:**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-14-027.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=RFA-HD-14-027>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Transmission of HIV/AIDS, AIDS, HIV Infection, Drug Delivery Systems, Disease Prevention, Retrovirus, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Clinical Laboratory Science, Community-based Clinical Subjects

**Contact Details**

-----  
Maternal and Pediatric Infectious Disease Branch

NICHD

NIH

6100 Executive Boulevard, Room 4B11

Bethesda, MD 20892

Tel+1 301 496 7350

Email: [siberryg@mail.nih.gov](mailto:siberryg@mail.nih.gov)

SEPTEMBER 2013

**N**CI EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT PROGRAMME (R21):  
**AIDS-RELATED**  
NIH: National Cancer Institute

**Description:**

The National Cancer Institute invites Aids-related applications for its exploratory/developmental research grant programme for cancer research (R21). This Aids-related R21 funding opportunity announcement supports the developmental of new research activities in all areas of cancer research. The mechanism is intended to encourage exploratory and developmental research projects by exploring support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models or applications that could have a major impact on a field of cancer research, either biomedical, behavioural or clinical.

Application budgets are limited to US\$275,000 over a two-year project period, with no more than US\$200,000 available in any year. PAR-13-146 (replaces PAR-12-145).

**Closing date: 05 Sep 13**

**Deadline information: Proposals due by 5pm applicant's local time on 5 September 2013; 5 January, 5 May and 5 September 2014; 5 January, 5 May and 4 September 2015.**

**Posted date: 20 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-146.html>

**Application form:**

<http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Transmission of HIV/AIDS, Economics, Feasibility Studies, Cancer Biology, AIDS, Breast Cancer, Cancer & Carcinogenesis, HIV Infection, Prostate Cancer, Tumour Immunology, Methodologies & Procedures (Health & Safety & Medical), Nursing, Oncology, Anatomy, Computer Sciences, Data Analysis, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Nursing (RAE Unit 10), Computer Science (RAE Unit 25), Economics and Econometrics (RAE Unit 38), Cancer Care, Leukaemia, Clinical Laboratory Science, Brain Tumour, Oncology Nursing, Blood Cancer, Cancer Nanotechnology, Hospital-based Clinical Subject, Physiology, Lung Cancer, Ovarian Cancer, Colorectal Cancer/Colon Cancer/Bowel Cancer, Skin Cancer

**Contact Details**

-----  
National Cancer Institute  
6116 Executive Boulevard  
Suite 300  
Bethesda MD 20892-8322

## **R** **RESEARCH ON ALCOHOL AND HIV/AIDS (R21)** *NIH: National Institute on Alcohol Abuse and Alcoholism*

### **Description:**

The National Institute on Alcohol Abuse and Alcoholism invites R21 applications for its research on alcohol and HIV/AIDS programme.

This supports small research projects that aim to:

- characterise the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV, in order to identify and apply appropriate alcohol and HIV interventions as public health measures;
- more fully understand and prevent the progression of HIV in the presence of continued alcohol exposure;
- develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations, such as minority women and gay men, and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.

This funding opportunity announcement will utilise the R21 grant mechanism and runs in parallel with two funding opportunity announcements of identical scientific scope that solicit applications under the R01 and R03 mechanisms.

Direct costs are limited to \$275,000 over an R21 two-year period, with no more than \$200,000 in direct costs allowed in any single year.

Applications may be submitted by domestic and foreign for-profit and non-profit

organisations and public or private institutions.

PA-13-122.

**Closing date: 07 Sep 13**

**Deadline information: Applications due by 5pm proposer's local time every 7 January, 7 May, 7 September until 8 May 2016.**

**Posted date: 22 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-10-105.html>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Homosexual, Male, Minorities & Disadvantaged, Alcohol & Alcoholism, Drug & Substance Abuse, Transmission of HIV/AIDS, Sexual Behaviour, Medical Sociology, Behaviour & Health, AIDS, HIV Infection, Social & Economic Environment (Medical), Public Health, Intervention, Types of (Health & Safety & Medical), Disease Prevention, Pathogenesis, Epidemiology, Disease Control, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Other Studies and Professions Allied to Medicine (RAE Unit 11), Psychology (RAE Unit 13), Social Policy and Administration (RAE Unit 40), Sociology (RAE Unit 42), Clinical Laboratory Science, Health Disparities, Other Studies and Professions Allied to Medicine, Women's Health

### **Contact Details**

-----  
Fax: +1 301 403 9289

Email: [kbryant@mail.nih.gov](mailto:kbryant@mail.nih.gov)

## **R** **ESearch ON ALCOHOL AND HIV/AIDS (R03)** *NIH: National Institute on Alcohol Abuse and Alcoholism*

### **Description:**

The National Institute on Alcohol Abuse and Alcoholism invites R03 applications for its research on alcohol and HIV/AIDS programme.

This supports small research projects that aim to:

- characterise the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV, in order to identify and apply appropriate alcohol and HIV interventions as public health measures;
- more fully understand and prevent the progression of HIV in the presence of continued alcohol exposure;
- develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations, such as minority women and gay men, and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.

The R03 grant mechanism is intended to support small research projects that can be carried out in a short period of time with limited resources.

This funding opportunity announcement will utilise the R03 grant mechanism and runs in parallel with two funding opportunity announcements of identical scientific scope that solicit applications under the R01 and R21 mechanisms. Projects may request direct costs of US\$50,000 over a maximum of two years.

Applications may be submitted by domestic and foreign for-profit and non-profit

organisations and public or private institutions.

PA-13-120.

**Closing date: 07 Sep 13**

**Deadline information: Applications due by 5pm proposer's local time every 7 January, 7 May, 7 September until 8 May 2016.**

**Posted date: 22 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$50,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-120.html>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Homosexual, Male, Minorities & Disadvantaged, Alcohol & Alcoholism, Drug & Substance Abuse, Transmission of HIV/AIDS, Sexual Behaviour, Medical Sociology, Behaviour & Health, AIDS, HIV Infection, Social & Economic Environment (Medical), Public Health, Intervention, Types of (Health & Safety & Medical), Disease Prevention, Pathogenesis, Epidemiology, Disease Control, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Other Studies and Professions Allied to Medicine (RAE Unit 11), Psychology (RAE Unit 13), Social Policy and Administration (RAE Unit 40), Sociology (RAE Unit 42), Clinical Laboratory Science, Health Disparities, Other Studies and Professions Allied to Medicine, Women's Health

### **Contact Details**

-----  
Fax: +1 301 403 9289

Email: [kbryant@mail.nih.gov](mailto:kbryant@mail.nih.gov)

## **A** IDS-SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03) NIH: National Institute on Drug Abuse

### **Description:**

The National Institute on Drug Abuse invites applications for its Aids-science track award for research transition programme. This R03 funding opportunity announcement seeks to facilitate the entry of new and early-career investigators to the area of drug abuse research on HIV/Aids. To promote the entry of new investigators into research on the natural history, epidemiology, aetiology and pathogenesis, prevention and treatment of Aids in drug abusers, the FOA will support the following types of projects:

- pilot or feasibility studies;
- secondary analysis of existing data;
- small, self-contained research projects;
- development of research methodology;
- development of new research technology.

Applicants may request direct costs of up to US\$100,000 per year over a project duration of up to two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-282 (replaces PAR-10-021).

**Closing date: 07 Sep 13**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Deadlines on: 7 September 2013, 7 September 2014, 7 September 2015.**

**Posted date: 11 Sep 12**

**Award type: Directed grants to institutions, research groups etc, Innovation grants**

**Award amount max: \$200,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-282.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-282>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Drug & Substance Abuse, Transmission of HIV/AIDS, AIDS, HIV Infection, Disease Prevention, Preventive Medicine, Treatment, Medical, Aetiology, Natural History of Disease, Pathogenesis, Epidemiology, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Clinical Laboratory Science, Community-based Clinical Subjects

**Contact Details**

-----  
Division of Clinical Neuroscience and Behavioural Research

National Institute on Drug Abuse

NIH/DHHS

6001 Executive Boulevard

Room 3152, MSC 9593

Bethesda, MD 20892-9593

Tel: +1 301 443 3207

Fax: +1 301 443 6814

Email: [aklinwm@mail.nih.gov](mailto:aklinwm@mail.nih.gov)



**S** MALL GRANTS FOR NEW INVESTIGATORS TO PROMOTE DIVERSITY IN HEALTH-RELATED RESEARCH (R03): AIDS-RELATED  
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

**Description:**

The National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Mental Health and the Office of Dietary Supplements invite applications for Aids-related small grants for new investigators to promote diversity in health-related research (R03). This Aids-related R03 funding opportunity announcement will provide support for new investigators from underrepresented backgrounds to conduct small research projects in the areas of research relevant to the sponsoring institutes. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources.

Direct costs are limited to US\$125,000 per year for a maximum of three years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PAR-13-074 (replaces PAR-09-223).

**Closing date: 07 Sep 13**

**Deadline information: Applications due annually on 7 September until 8 September 2015. Deadlines on: 7 September 2013, 7 September 2014, 7 September 2015.**

**Posted date: 08 Jan 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$375,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-074.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-074>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Nutrition & Dietetics, AIDS, Diabetes, Digestive Diseases & Disorders, HIV Infection, Kidney Disease, Obesity, Metabolism, Endocrinology, Haematology, Urology, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Hospital-based Clinical Subject

**Contact Details**

-----  
Office of Minority Health Research Coordination  
NIDDK  
6707 Democracy Boulevard  
II Democracy Plaza, Room 906-B,  
MSC 5454  
Bethesda, MD 20892-5454  
Tel: +1 301 594 9652  
Email: [mcbrydekd@mail.nih.gov](mailto:mcbrydekd@mail.nih.gov)





## **U**NDERSTANDING AND PROMOTING HEALTH LITERACY (R03): AIDS-RELATED NIH: Office of the Director

**Description:** A total of eight institutes and offices of the National Institutes of Health invite proposals for the Aids-related understanding and promoting health literacy (R03) programme. The goal of this Aids-related R03 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R03 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-130, which uses the R01 grant mechanism, and PAR-13-132, which uses the R21 grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Direct costs are limited to US\$100,000 over two years with no more than US\$50,000 in any year. PAR-13-132 (replaces PAR-10-134).

**Closing date: 07 Sep 13**

**Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until May 8, 2013.**

**Posted date: 04 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-131.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-131>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
AIDS, HIV Infection, Education & Instruction (Health & Safety & Medical), Health Care, Patient Care & Education, Public Health, Health Promotion, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Education (RAE Unit 68), Health Education, Community-based Clinical Subjects, Hospital-based Clinical Subject

**Contact Details**

-----  
OBSSR

NIH

31 Centre Drive, Room B1C19

Bethesda, MD 20814

Tel: +1 301 401 0116

Email: [elwoodwi@od.nih.gov](mailto:elwoodwi@od.nih.gov)

---

## **U**NDERSTANDING AND PROMOTING HEALTH LITERACY (R21): AIDS-RELATED NIH: Office of the Director

**Description:**

A total of nine institutes and offices of the National Institutes of Health invite proposals

for the Aids-related understanding and promoting health literacy (R21) programme. The goal of this Aids-related R21 funding

opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R21 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-130, which uses the R01 grant mechanism, and PAR-13-131, which uses the R03 grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Direct costs are limited to US\$275,000 over two years with no more than US\$200,000 available in any year. PAR-13-132 (replaces PAR-10-135).

**Closing date: 07 Sep 13**

**Deadline information: Applications due by 5pm local time of applicant institution on every 7 January, 7 May and 7 September until May 8, 2013.**

**Posted date: 04 Mar 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-132.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-132>

**Eligibility profile**


-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
AIDS, HIV Infection, Education & Instruction (Health & Safety & Medical), Health Care, Patient Care & Education, Public Health, Health Promotion, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Education (RAE Unit 68), Health Education, Community-based Clinical Subjects, Hospital-based Clinical Subject

**Contact Details**

-----  
OBSSR  
NIH  
31 Centre Drive, Room B1C19  
Bethesda, MD 20814  
Tel: +1 301 401 0116  
Email: [elwoodwi@od.nih.gov](mailto:elwoodwi@od.nih.gov)



**S**CHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R21): AIDS-RELATED  
*NIH: National Institute of Child Health and Human Development*

**Description:**

A total of four institutes and offices of the National Institutes of Health invites applications for their Aids-related school nutrition and physical activity policies, obesogenic behaviours and weight outcomes (R21) grants. The objectives of this Aids-related R21 funding opportunity announcement are to understand how

school-related policies impact the school and home environment, promote positive nutrition and physical activity behaviours and decrease childhood obesity. Applications should propose to:

- foster multidisciplinary research that will evaluate how policies can influence school physical activity and

nutrition environments, youths' obesogenic behaviours and weight outcomes;

- understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
- understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with two FOAs of identical scope, PAR-13-099, which uses the R03 small grant programme mechanism, and PAR-13-100, which uses the R01 research project grant mechanism.

Application budgets are limited to US\$275000 over a two-year project period, with no more than US\$200,000 in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-098.

**Closing date: 07 Sep 13**

**Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.**

**Posted date: 04 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-098.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-098>

#### Eligibility profile

---

Nationality of applicant institution: Any

#### Disciplines

---

Educational Planning & Policy, Nutrition Education, Physical Education, Behaviour & Health, Nutrition & Dietetics, AIDS, HIV Infection, Obesity, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Psychology (RAE Unit 13), Social Policy and Administration (RAE Unit 40), Education (RAE Unit 68), Sports-related Subjects (RAE Unit 69), Sport & Dance Education, Health Education, Clinical Laboratory Science, Community-based Clinical Subjects

#### Contact Details

---

NICHD

6100 Executive Boulevard, Room 4B05  
Rockville, MD 20852

Tel: +1 301 435 6888

Email: [espositl@mail.nih.gov](mailto:espositl@mail.nih.gov)

---

## **S**CHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R03): AIDS-RELATED

*NIH: National Institute of Child Health and Human Development*

#### **Description:**

A total of three institutes and offices of the National Institutes of Health invites applications for their Aids-related school

nutrition and physical activity policies, obesogenic behaviours and weight outcomes (R03) grants. The objectives of this Aids-related R03 funding opportunity

announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity behaviours and decrease childhood obesity. Applications should propose to:

- foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths' obesogenic behaviours and weight outcomes;
- understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
- understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R03 small grant programme mechanism and runs in parallel with two FOAs of identical scope, PAR-13-098, which uses the R21 exploratory/developmental research grant mechanism, and PAR-13-100, which uses the R01 research project grant mechanism.

Application budgets are limited to US\$50,000 per year over a two-year project period. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-099.

**Closing date: 07 Sep 13**

**Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.**

**Posted date: 04 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-099.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-099>

**Eligibility profile**

-----

Nationality of applicant institution: Any

**Disciplines**

-----

Educational Planning & Policy, Nutrition Education, Physical Education, Behaviour & Health, Nutrition & Dietetics, AIDS, HIV Infection, Obesity, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Psychology (RAE Unit 13), Social Policy and Administration (RAE Unit 40), Education (RAE Unit 68), Sports-related Subjects (RAE Unit 69), Sport & Dance Education , Health Education , Clinical Laboratory Science, Community-based Clinical Subjects

**Contact Details:**

-----

NICHHD

6100 Executive Boulevard, Room 4B05

Rockville, MD 20852

Tel: +1 301 435 6888

Email: [espositl@mail.nih.gov](mailto:espositl@mail.nih.gov)



---

## **R**EGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21): AIDS-RELATED *NIH: National Institute on Aging*

### **Description:**

The National Institute on Aging invites R21 Aids-related applications for its regional and international differences in health and longevity at older ages grants.

Aids-related applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialised nations and across geographical areas in the United States.

This FOA will utilise the R21 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

The combined budget for direct costs may not exceed US\$275,000 over two years. no more than US\$200,000 per year may be requested.

PA-13-124.

**Closing date: 07 Sep 13**

**Deadline information: Applications due 5pm proposer's local time, 7 January, 7 May**

and 7 September annually until 8 September 2016.

**Posted date: 22 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-124.html>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Life Expectancy, Transmission of HIV/AIDS, Psychology, Psychology of Ageing, Ageing & Gerontology, Population Studies (Medical), AIDS, HIV Infection, International Health, Community-based Clinical Subjects (RAE Unit 2), Psychology (RAE Unit 13), Social Policy and Administration (RAE Unit 40), Health Disparities, Community-based Clinical Subjects, HIV/AIDS, Social Aspects, Quality of Life, Social Inequality

### **Contact Details**

-----  
Fax: +1 301 496 3138

Email: [patmiosg@nia.nih.gov](mailto:patmiosg@nia.nih.gov)

---

## **R**EGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R03): AIDS-RELATED *NIH: National Institute on Aging*

### **Description:**

The National Institute on Aging invites R03 Aids-related applications for its regional and international differences in health and longevity at older ages grants.

Aids-related applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both

across industrialised nations and across geographical areas in the United States.

This FOA will utilise the R03 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

The combined budget for direct costs may not exceed US\$100,000 over two years. no more than US\$50,000 per year may be requested.

PA-13-123.

**Closing date: 07 Sep 13**

**Deadline information: Applications due 5pm proposer's local time, 7 January, 7 May and 7 September annually until 8 September 2016.**

**Posted date: 22 Feb 13**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-13-123.html>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Life Expectancy, Transmission of HIV/AIDS, Psychology, Psychology of Ageing, Ageing & Gerontology, Population Studies (Medical), AIDS, HIV Infection, International Health, Community-based Clinical Subjects (RAE Unit 2), Psychology (RAE Unit 13), Social Policy and Administration (RAE Unit 40), Health Disparities, Community-based Clinical Subjects, HIV/AIDS, Social Aspects, Quality of Life, Social Inequality

**Contact Details:**

-----  
Fax: +1 301 496 3138

Email: [patmiosg@nia.nih.gov](mailto:patmiosg@nia.nih.gov)



**NIDA RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25): AIDS-RELATED**  
*NIH: National Institute on Drug Abuse*

**Description:**

The National Institute on Drug Abuse invites applications for its Aids-related research education programme for clinical researchers and clinicians (R25) grants. This R25 funding opportunity announcement will support research education for those in clinically focused careers, in a topic area related to substance use, abuse or addiction. Participants should be training for careers as clinical researchers, clinicians or service providers, or optimally a combination of the two. This mechanism may not be used to support non-related-related clinical training.

Direct costs are limited to US\$350,000 in direct costs allowed in any single year. The maximum project period is five years. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-084 (replaces PAR-10-173).

**Closing date: 09 Sep 13**

**Deadline information: Applications due by 5pm proposer's local time. Deadlines on: 9 September 2013, 8 September 2014, 7 September 2015.**

**Posted date: 11 Jan 13**

**Award type: Directed grants for individual investigators, Personal development**

**Award amount max: \$1,750,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-13-084.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-084>

### Eligibility profile

-----

Nationality of applicant institution: Any

### Disciplines

-----

Drug & Substance Abuse, AIDS, HIV Infection, Clinical Medicine, General, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE

Unit 2), Hospital-based Clinical Subjects (RAE Unit 3), Clinical Laboratory Science, Community-based Clinical Subjects, Hospital-based Clinical Subject

### Contact Details:

-----

Behavioural and Integrative Treatment Branch

Division of Clinical Neuroscience and Behavioural Research

NIDA

6001 Executive Boulevard, Room 3157, MSC 9551

Bethesda, MD 20892-9551

Tel: +1 301 443 0107

Fax: +1 301 443 6814

Email: [dg79a@nih.gov](mailto:dg79a@nih.gov)



## **I**NTERVENTIONS FOR SIDS AND OTHER SLEEP RELATED INFANT DEATHS (R01)

*NIH: National Institute of Child Health and Human Development*

### **Description:**

The National Institute of Child Health and Human Development and the Centers for Disease Control invite applications for their interventions for SIDS and other sleep related infant deaths (R01) grants. This R01 funding opportunity announcement supports research to improve the design, implementation and effectiveness of preventive interventions for Sudden Infant Death Syndrome (SIDS) and unintentional injury infant deaths associated with the sleep environment. NICHD is interested in interventions that demonstrate changes in risk behaviour and environments and in studies on a particular population or geographic area or nationwide studies.

This FOA will utilize the R01 research project grant mechanism. Application budgets are not limited but need to reflect the actual

needs of the project. The total project period may not exceed five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-242

**Closing date: 12 Sep 13 (Forecast)**

**Deadline information: !! Call has not yet been announced by sponsor but this is the approximate deadline we expect. Deadline: letters of intent, August 13, annually, full applications, September 13, annually until September 14, 2013. This call is repeated once a year.**

**Posted date: 11 Jul 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-242.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-11-242>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Sociology, Sudden Infant Death Syndrome, Paediatrics, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Sociology (RAE Unit 42), Clinical Laboratory Science, Hospital-based Clinical Subject

**Contact Details**

National Institute of Child Health and Human Development

Tel: +1 301 435 6896

Email: [willingm@mail.nih.gov](mailto:willingm@mail.nih.gov)

---

**NHLBI SYSTEMS BIOLOGY COLLABORATIONS (R01)**  
*NIH: National Heart, Lung and Blood Institute*

**Description:**

The National Heart, Lung and Blood Institute invites grant applications for its systems biology collaborations (R01). This R01 funding opportunity announcement funds collaborative systems biology research projects by multi-disciplinary teams to advance understanding of normal physiology and perturbations associated with heart, lung, blood, and sleep diseases and disorders. Multi-disciplinary expertise across experimental and computational domains is required and the multi-PI mechanism is allowed, as integration across these domains is a critical element of the proposed research plan. The goal of this funding opportunity announcement is to improve our understanding of complex HLBS biological systems through the development of predictive mathematical models that make new testable predictions of how the biological system will respond to perturbations seen during development, adaptation, or disease. The mathematical model proposed in the application must recapitulate the known characteristics of a biological system and predict responses of

the system to novel perturbations. While bioinformatic and statistical expertise may be essential components of research proposed under this FOA, applications must include predictive, mechanistic, quantitative models that generate testable hypotheses about the physiological and pathophysiological mechanisms that underlie the responses to perturbation.

Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. The maximum project period is five years. PAR-12-138 (replaces PAR-09-214).

**Closing date: 13 Sep 13**

**Deadline information: Deadline: 14 September 2012; 14 January, 13 September 2013; 13 January, 15 September 2015.**

**Posted date: 26 Mar 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**



**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-138.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-138>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Heart, Respiratory System, Blood Diseases, Cardiovascular Diseases, Lung Disease, Sleep Disorders, Mathematical Model (Medical), Cardiology, Haematology, Clinical

Laboratory Sciences (RAE Unit 1), Biological Sciences (RAE Unit 14), Applied Mathematics (RAE Unit 23), Systems Biology, Clinical Laboratory Science

**Contact Details:**

Blood Disease Branch  
Division of Blood Diseases and Resources  
National Heart, Lung, and Blood Institute  
NIH  
6701 Rockledge Drive, MSC 7950  
Bethesda, MD 20892-7940  
Tel: +1 301 435 0050  
Fax: +1 301 480 0867  
Email: [gasbap@nhlbi.nih.gov](mailto:gasbap@nhlbi.nih.gov)

---

**GENETIC SCREENS TO ENHANCE ZEBRAFISH RESEARCH (R01)**  
*NIH: National Institute of Child Health and Human Development*

**Description:**

A total of 10 components of the National Institutes of Health are inviting grant applications for their genetic screens to enhance zebrafish research (R01) grants. This funding opportunity encourages investigator-initiated applications designed to exploit the power of the zebrafish as a vertebrate model for biomedical and behavioral research. Applications proposing to develop new genetic screens of high priority to the zebrafish community that will advance the detection and characterization of genes, pathways, and phenotypes of interest in development and aging, organ formation, neural processes, behavior, sensory processing, physiological processes, and disease processes are welcome.

This funding opportunity will utilize the NIH research project grant (R01) grant mechanism. Budgets for direct costs under \$500,000 per year and a project duration of up to five years may be requested. Eligible

applicants include domestic and foreign public or private institutions and non-profit or for-profit organizations. PAR-11-130 (replaces PAR-08-138)

**Closing date: 19 Sep 13**

**Deadline information: Deadline: letters of receipt August 19; full applications September 19, 2011, 2012 and 2013.**

**Posted date: 05 Apr 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$2,500,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-130.html>

**Application form:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-130.html>

**Eligibility profile**

Nationality of applicant institution: Any

## Disciplines

-----

Gene Therapy, Proteins & Macromolecules, Gene Expression, Organs, Medical Genetics, Neurology, Biological Modelling, Physiology, Vertebrate, Biology, Behavioural, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Physiology (RAE Unit 7), Biological Sciences (RAE Unit 14), Clinical Laboratory Science, Hospital-based Clinical Subject, Physiology, Animal Models

## Contact Details

-----

Eunice Kennedy Shriver National Institute of Child Health and Human Development  
6100 Executive Boulevard, Room 4B01, MSC 7510  
Bethesda, MD 20892-7510  
Tel: +1 301 496 5541  
Email: [javoisl@nih.gov](mailto:javoisl@nih.gov)



## **S** TUDIES IN NEONATAL RESUSCITATION (R01)

*NIH: National Institute of Child Health and Human Development*

### **Description:**

The National Institute of Child Health and Human Development invites applications for its studies in neonatal resuscitation (R01) grants. This R01 funding opportunity announcement seeks to stimulate research on a wide range of topics related to neonatal resuscitation.

The research can be basic or applied, experimental or observational, and clinical or translational. Possible topics may include:

- fetal-neonatal transitional cardiovascular and pulmonary physiology;
- optimizing steps of resuscitation;
- management of third stage of labor and its effect of the fetus;
- resuscitation of children with malformations;
- effect of resuscitation on long-term outcomes.

It is anticipated that the results from well conducted studies will enable transition for a healthy beginning and lay a foundation for optimal short- and long-term outcomes for all newborn infants.

This FOA will utilize the R01 mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-11-223 that encourages applications under the R03 small grant program mechanism and PAR-11-224 that encourages applications under the R21 exploratory/developmental grant mechanism.

Application budgets are not limited but need to reflect the actual needs of the project. The total project period may not exceed five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-222

**Closing date: 19 Sep 13**

**Deadline information: Deadline: letters of intent, August 19; full applications September 19 annually until September 20, 2013.**

**Posted date: 09 Jun 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-222.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-222>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Cardiovascular System, Foetus, Neonatal Disorders, Obstetrics & Gynaecology, Paediatrics, Anatomy, Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Other

Studies and Professions Allied to Medicine (RAE Unit 11), Hospital-based Clinical Subject, Other Studies and Professions Allied to Medicine, Physiology

**Contact Details**

-----  
Pregnancy and Perinatology Branch  
Center for Developmental Biology and Perinatal Medicine

NICHD

6100 Executive Boulevard, Room 4B03

Bethesda, MD 20892-7510

Tel: +1 301 402 1872

Fax: +1 301 496 6790

Email: [rajut@mail.nih.gov](mailto:rajut@mail.nih.gov)



## **S** TUDIES IN NEONATAL RESUSCITATION (R03)

*NIH: National Institute of Child Health and Human Development*

**Description:**

The National Institute of Child Health and Human Development invites applications for its studies in neonatal resuscitation (R03) grants. This R03 funding opportunity announcement seeks to stimulate research on a wide range of topics related to neonatal resuscitation.

The research can be basic or applied, experimental or observational, and clinical or translational. Possible topics may include:

- fetal-neonatal transitional cardiovascular and pulmonary physiology;
- optimizing steps of resuscitation;
- management of third stage of labor and its effect of the fetus;
- resuscitation of children with malformations;
- effect of resuscitation on long-term outcomes.

It is anticipated that the results from well conducted studies will enable transition for a healthy beginning and lay a foundation for optimal short- and long-term outcomes for all newborn infants.

This FOA will utilize the R03 mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-11-222 that encourages applications under the R01 research project grant mechanism and PAR-11-224 that encourages applications under the R21 exploratory/developmental grant mechanism.

Application budgets are limited to 50,000 in direct costs per year. The total project period may not exceed two years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-223

**Closing date: 19 Sep 13**

**Deadline information:** Deadline: letters of intent, August 19; full applications September 19 annually until September 20, 2013.

**Posted date:** 09 Jun 11

**Award type:** Directed grants to institutions, research groups etc

**Award amount max:** \$100,000

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-11-223.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-223>

**Eligibility profile**

Nationality of applicant institution: Any

**Disciplines**

Cardiovascular System, Foetus, Neonatal Disorders, Obstetrics & Gynaecology, Paediatrics, Anatomy, Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Other Studies and Professions Allied to Medicine (RAE Unit 11), Hospital-based Clinical Subject, Other Studies and Professions Allied to Medicine, Physiology

**Contact Details**

Pregnancy and Perinatology Branch  
Center for Developmental Biology and Perinatal Medicine  
NICHD  
6100 Executive Boulevard, Room 4B03  
Bethesda, MD 20892-7510  
Tel: +1 301 402 1872  
Fax: +1 301 496 6790  
Email: [rajut@mail.nih.gov](mailto:rajut@mail.nih.gov)

---

## **S** TUDIES IN NEONATAL RESUSCITATION (R21)

*NIH: National Institute of Child Health and Human Development*

### **Description:**

The National Institute of Child Health and Human Development invites applications for its studies in neonatal resuscitation (R21) grants. This R21 funding opportunity announcement seeks to stimulate research on a wide range of topics related to neonatal resuscitation.

The research can be basic or applied, experimental or observational, and clinical or translational. Possible topics may include:

- fetal-neonatal transitional cardiovascular and pulmonary physiology;
- optimizing steps of resuscitation;
- management of third stage of labor and its effect of the fetus;
- resuscitation of children with malformations;

- effect of resuscitation on long-term outcomes.

It is anticipated that the results from well conducted studies will enable transition for a healthy beginning and lay a foundation for optimal short- and long-term outcomes for all newborn infants.

This FOA will utilize the R21 mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-11-222 that encourages applications under the R01 research project grant mechanism and PAR-11-223 that encourages applications under the R03 small grant program mechanism.

Application budgets are limited to 275,000 in direct costs over a two-year period. The total project period may not exceed two years.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-224

**Closing date: 19 Sep 13**

**Deadline information: Deadline: letters of intent, August 19; full applications September 19 annually until September 20, 2013.**

**Posted date: 09 Jun 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**<http://grants.nih.gov/grants/guide/pa-files/PA11-224.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFormFedgrants?opportunity=PAR-11-224>

**Eligibility profile**

Nationality of applicant institution: Any

### Disciplines

Cardiovascular System, Foetus, Neonatal Disorders, Obstetrics & Gynaecology, Paediatrics, Anatomy, Hospital-based Clinical Subjects (RAE Unit 3), Anatomy (RAE Unit 6), Physiology (RAE Unit 7), Other Studies and Professions Allied to Medicine (RAE Unit 11), Hospital-based Clinical Subject, Other Studies and Professions Allied to Medicine, Physiology

### Contact Details

Pregnancy and Perinatology Branch  
Center for Developmental Biology and Perinatal Medicine  
NICHD  
6100 Executive Boulevard, Room 4B03  
Bethesda, MD 20892-7510  
Tel: +1 301 402 1872  
Fax: +1 301 496 6790  
Email: [rajut@mail.nih.gov](mailto:rajut@mail.nih.gov)

---

## **P**ATIENT SAFETY RESEARCH DURING NEONATAL CARE (R01)

*NIH: National Institute of Child Health and Human Development*

### Description:

The National Institute of Child Health and Human Development invites applications for its patient safety research during neonatal care (R01) grants. This R01 funding opportunity announcement encourages a wide range of collaborative research projects related to patient safety in the context of both routine as well as intensive newborn care. The FOA welcomes proposals related to:

- the epidemiology of various domains of medical errors and consequent patient harm;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;

- other working conditions and systems issues;
- assessing the factors at various levels that contribute to such errors;
- intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors in the context neonatal care.

It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality healthcare to all newborn infants with utmost safety and effectiveness.

This FOA will utilize the R01 mechanism and runs in parallel with two FOAs of identical

scientific scope, PAR-11-226 that encourages applications under the R03 small grant program mechanism and PAR-11-227 that encourages applications under the R21 exploratory/developmental grant mechanism.

Application budgets are not limited but need to reflect the actual needs of the project. The total project period may not exceed five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-225

**Closing date: 19 Sep 13**

**Deadline information: Deadline: letters of intent August 19; full applications 5pm September 19, annually until September 20, 2013.**

**Posted date: 13 Jun 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-225.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-225>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Neonatal Disorders, Health Care Quality & Effectiveness, Patient Care & Education, Methodologies & Procedures (Health & Safety & Medical), Children (Patients), Epidemiology, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Medical and Biotechnology (Diagnostics), Hospital-based Clinical Subject, Medication Studies

**Contact Details**

-----  
Pregnancy and Perinatology Branch

CDBPM

NICHD

6100 Executive Boulevard, Room 4B03

Bethesda, MD 20892-7510

Tel: +1 301 402 1872

Fax: +1 301 496 6790

Email: [rajut@mail.nih.gov](mailto:rajut@mail.nih.gov)



## **P**ATIENT SAFETY RESEARCH DURING NEONATAL CARE (R03)

*NIH: National Institute of Child Health and Human Development*

### **Description:**

The National Institute of Child Health and Human Development invites applications for its patient safety research during neonatal care (R03) grants. This R03 funding opportunity announcement encourages a wide range of collaborative research projects related to patient safety in the context of both routine as well as intensive newborn care. The FOA welcomes proposals related to:

- the epidemiology of various domains of medical errors and consequent patient harm;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- other working conditions and systems issues;

- assessing the factors at various levels that contribute to such errors;
- intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors in the context neonatal care.

It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality healthcare to all newborn infants with utmost safety and effectiveness.

This FOA will utilize the R03 mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-11-225 that encourages applications under the R01 research grant program mechanism and PAR-11-227 that encourages applications under the R21 exploratory/developmental grant mechanism.

Application budgets are limited to direct costs of up \$50,000 per year for a maximum \$100,000 over the two-year period. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-226

**Closing date: 19 Sep 13**

**Deadline information: Deadline: letters of intent August 19; full applications 5pm September 19, annually until September 20, 2013.**

**Posted date: 13 Jun 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$100,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-226.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-226>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Neonatal Disorders, Health Care Quality & Effectiveness, Patient Care & Education, Methodologies & Procedures (Health & Safety & Medical), Children (Patients), Epidemiology, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Medical and Biotechnology (Diagnostics), Hospital-based Clinical Subject, Medication Studies

**Contact Details**

-----  
Pregnancy and Perinatology Branch  
CDBPM  
NICHD  
6100 Executive Boulevard, Room 4B03  
Bethesda, MD 20892-7510  
Tel: +1 301 402 1872  
Fax: +1 301 496 6790  
Email: [rajut@mail.nih.gov](mailto:rajut@mail.nih.gov)

---

**P**ATIENT SAFETY RESEARCH DURING NEONATAL CARE (R21)  
*NIH: National Institute of Child Health and Human Development*

**Description:**

The National Institute of Child Health and Human Development invites applications for its patient safety research during neonatal

care (R03) grants. This R21 funding opportunity announcement encourages a wide range of collaborative research projects related to patient safety in the context of both

routine as well as intensive newborn care. The FOA welcomes proposals related to:

- the epidemiology of various domains of medical errors and consequent patient harm;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- other working conditions and systems issues;
- assessing the factors at various levels that contribute to such errors;
- intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors in the context neonatal care.

It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality healthcare to all newborn infants with utmost safety and effectiveness.

This FOA will utilize the R21 mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-11-225 that encourages applications under the R01 research grant program mechanism and PAR-11-226 that encourages applications under the R03 small grant program mechanism.

Application budgets are limited to direct costs of up \$275,000 over a two-year project period and no more than \$200,000 may be requested in any one year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-11-227

**Closing date: 19 Sep 13**

**Deadline information: Deadline: letters of intent August 19; full applications 5pm September 19, annually until September 20, 2013.**

**Posted date: 13 Jun 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-227.html>

**Application**

**form:**<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-227>

**Eligibility profile**

-----  
Nationality of applicant institution: Any

**Disciplines**

-----  
Neonatal Disorders, Health Care Quality & Effectiveness, Patient Care & Education, Methodologies & Procedures (Health & Safety & Medical), Children (Patients), Epidemiology, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Pharmacology (RAE Unit 8), Medical and Biotechnology (Diagnostics), Hospital-based Clinical Subject, Medication Studies

**Contact Details**

-----  
Pregnancy and Perinatology Branch  
CDBPM  
NICHD  
6100 Executive Boulevard, Room 4B03  
Bethesda, MD 20892-7510  
Tel: +1 301 402 1872  
Fax: +1 301 496 6790  
Email: [rajut@mail.nih.gov](mailto:rajut@mail.nih.gov)





## **E**NHANCING ZEBRAFISH RESEARCH WITH RESEARCH TOOLS AND TECHNIQUES **(R01)** NIH: National Institute of Diabetes and Digestive and Kidney Diseases

### **Description:**

A total of 13 components of the National Institutes of Health invite grant applications for their enhancing zebrafish research with research tools and techniques (R01) grants. Applications will be accepted that seek to develop new research tools and techniques that are of high priority to the zebrafish community and that will advance the detection and characterization of genes, pathways and phenotypes of interest in development and processing, physiological processes and disease processes. The focus of the application must be restricted to development of the screening tool and a small pilot or validation screen.

This funding opportunity will utilize the NIH research project grant (R01) grant mechanism. Budgets for direct costs under \$500,000 per year and a project duration of up to five years may be requested. Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organizations. PAR-11-131 (replaces PAR-08-139)

**Closing date: 19 Sep 13**

**Deadline information: Deadline: letters of receipt August 19; full applications September 19, 2011, 2012 and 2013.**

**Posted date: 05 Apr 11**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$2,500,000**

### **Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-131.html>

### **Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-131>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Gene Therapy, Proteins & Macromolecules, Gene Expression, Organs, Medical Genetics, Neurology, Biological Modelling, Physiology, Vertebrate, Biology, Behavioural, Clinical Laboratory Sciences (RAE Unit 1), Hospital-based Clinical Subjects (RAE Unit 3), Physiology (RAE Unit 7), Biological Sciences (RAE Unit 14), Clinical Laboratory Science, Hospital-based Clinical Subject, Physiology, Animal Models

### **Contact Details**

-----  
National Institute of Diabetes and Digestive and Kidney Diseases/NIH  
Two Democracy Plaza  
6707 Democracy Blvd, MSC 5458  
Bethesda, MD 20892-5458  
Tel: +1 301 594 6007  
Fax :+1 301 480 3510  
Email: [rr185i@mail.nih.gov](mailto:rr185i@mail.nih.gov)

## **G**ENETIC AND GENOMIC ANALYSIS OF XENOPUS (R01) NIH: National Institute of Child Health and Human Development

### **Description:**

The National Institute of Child Health and Human Development, the National Institute on Deafness and Other Communication Disorders and the National Institute of General Medical Sciences, in collaboration with the trans-NIH xenopus working group, invite proposals for the genetic and genomic analysis of xenopus. This R01 funding opportunity announcement invites investigator-initiated applications designed to exploit the power of xenopus as a vertebrate model for biomedical research. Applications may propose to develop new tools or genetic, genomic or proteomic resources of high priority to the xenopus community that will advance the detection and characterisation of genes, pathways and phenotypes of interest in development, organogenesis and in cell biological processes, such as cell division, signalling and migration. This FOA welcomes applications that utilise the recently developed tools or resources to advance these goals, particularly when these projects employ tools that have not been previously used in xenopus research.

This FOA will utilise the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-12-249, which encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PAR-12-250 (replaces PAR-09-240)

**Closing date: 30 Sep 13**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Posted date: 26 Jul 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: -**

**Award amount min: -**

**Award budget total: -**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-250.html>

**Application form:**

<http://grants.nih.gov/grants/guide/pa-files/PAR-12-250.html>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Disease Model, Gene Expression, Gene Regulation, Biology, Cellular, Cell Migration, Human Development, Molecular Genetics, Mutagenics, Biochemistry, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Biological Sciences (RAE Unit 14), Genomics, Clinical Laboratory Science, Community-based Clinical Subjects, Screening For Diseases

### **Contact Details**

-----  
Developmental Biology and Teratology Branch

NICHD

6100 Executive Boulevard, Room 4B01B

Bethesda, MD 20892-7510

Tel: +1 301 451 1390

Fax: +1 301 480 0303

Email: [coulombej@mail.nih.gov](mailto:coulombej@mail.nih.gov)

## **G**ENETIC AND GENOMIC ANALYSIS OF XENOPUS (R21) NIH: National Institute of Child Health and Human Development

### **Description:**

The National Institute of Child Health and Human Development and the National Institute on Deafness and Other Communication Disorders, in collaboration with the trans-NIH xenopus working group, invite proposals for the genetic and genomic analysis of xenopus. This R21 funding opportunity announcement invites investigator-initiated applications designed to exploit the power of xenopus as a vertebrate model for biomedical research. Applications may propose to develop new tools or genetic, genomic or proteomic resources of high priority to the xenopus community that will advance the detection and characterisation of genes, pathways and phenotypes of interest in development, organogenesis and in cell biological processes, such as cell division, signalling and migration. This FOA welcomes applications that utilise the recently developed tools or resources to advance these goals, particularly when these projects employ tools that have not been previously used in xenopus research.

This FOA will utilise the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-250, which encourages applications under the NIH research project grant (R01) mechanism. Direct costs are limited to US\$275,000 over an R21 two-year period. Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PAR-12-249 (replaces PAR-09-241).

**Closing date: 30 Sep 13**

**Deadline information: Applications due by 5pm local time of applicant organisation.**

**Deadlines on: 1 October 2012, 30 September 2013, 30 September 2014.**

**Posted date: 26 Jul 12**

**Award type: Directed grants to institutions, research groups etc**

**Award amount max: \$275,000**

**Website:**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-249.html>

**Application form:**

<http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-249>

### **Eligibility profile**

-----  
Nationality of applicant institution: Any

### **Disciplines**

-----  
Disease Model, Gene Expression, Gene Regulation, Biology, Cellular, Cell Migration, Human Development, Molecular Genetics, Mutagenics, Biochemistry, Clinical Laboratory Sciences (RAE Unit 1), Community-based Clinical Subjects (RAE Unit 2), Biological Sciences (RAE Unit 14), Genomics, Clinical Laboratory Science, Community-based Clinical Subjects, Screening For Diseases

### **Contact Details**

-----  
Developmental Biology and Teratology Branch

NICHD

6100 Executive Boulevard, Room 4B01B

Bethesda, MD 20892-7510

Tel: +1 301 451 1390

Fax: +1 301 480 0303

Email: [coulombej@mail.nih.gov](mailto:coulombej@mail.nih.gov)